niacinamide and Disease Models, Animal studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.

Research Excerpts

Excerpt	Relevance	Reference
" This study assessed corneal and somatic hypersensitivity in male rats treated with paclitaxel and whether it was relieved by nicotinamide riboside (NR)."	8.12	Nicotinamide Riboside Alleviates Corneal and Somatic Hypersensitivity Induced by Paclitaxel in Male Rats. ( Aicher, SA; Blum, C; Hamity, MV; Hammond, DL; Hegarty, DM; Kolker, SJ; Langmack, L, 2022)
"In this study, we aim to verify whether swim training can improve lactate metabolism, NAD+ and NADH levels, as well as modify the activity of glycolytic and NADH shuttle enzymes and monocarboxylate transporters (MCTs) in skeletal muscle of amyotrophic lateral sclerosis (ALS) mice."	8.12	Swim Training Affects on Muscle Lactate Metabolism, Nicotinamide Adenine Dinucleotides Concentration, and the Activity of NADH Shuttle Enzymes in a Mouse Model of Amyotrophic Lateral Sclerosis. ( Antosiewicz, J; Cieminski, K; Dzik, KP; Flis, DJ; Kaczor, JJ; Wieckowski, MR; Ziolkowski, W, 2022)
"Sorafenib is the only approved targeted drug for hepatocellular carcinoma (HCC), but its effect on patients' survival gain is limited and varies over a wide range depending on pathogenetic conditions."	7.85	Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. ( Cho, EJ; Cho, H; Cho, KH; Cho, SH; Choi, WM; Hwang, CY; Jang, JJ; Kim, CY; Kim, K; Kim, YJ; Lee, JH; Lee, KB; Park, SM; Suh, KS; Won, JK; Yoon, JH; Yu, SJ, 2017)
"In a mouse model of HCC, effects of sorafenib were determined by tumor size, RFA-induced necrosis area (triphenyltetrazolium chloride staining), microvascular density (MVD; 4',6-diamidino-2-phenylindole and anti-CD31 antibody staining), and tumor perfusion (magnetic resonance imaging)."	7.85	Advantage of sorafenib combined with radiofrequency ablation for treatment of hepatocellular carcinoma. ( Chen, J; Fang, H; Jiang, B; Kang, M; Tang, Z; Wu, Y; Ye, Q; Zhang, B, 2017)
" Purpose To assess diagnostic values of intra-voxel incoherent motion (IVIM) imaging in evaluating therapeutic effects of sorafenib on hepatocellular carcinoma (HCC) using mouse xenograft model."	7.85	Intravoxel incoherent motion MRI for monitoring the therapeutic response of hepatocellular carcinoma to sorafenib treatment in mouse xenograft tumor models. ( Cheong, H; Hong, SM; Kim, N; Lee, CK; Lee, SS; Lee, Y; Son, WC, 2017)
"We have previously demonstrated that isocorydine (ICD) can be served as a potential antitumor agent in hepatocellular carcinoma (HCC)."	7.83	Derivate isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/M cell cycle arrest and apoptosis. ( Chen, L; Ge, C; Li, H; Li, J; Li, M; Liu, J; Tian, H; Wang, T; Yao, M; Zhang, L; Zhao, F, 2016)
"The anti-angiogenic Sorafenib is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC)."	7.83	Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma. ( Bar-Zion, A; Butz, H; Daley, F; Foster, FS; Kerbel, RS; Kuczynski, EA; Lee, CR; Man, S; Reynolds, AR; Vermeulen, PB; Yin, M; Yousef, GM, 2016)
"Sorafenib resistance remains a major obstacle for the effective treatment of hepatocellular carcinoma (HCC), and a number of miRNAs contribute to this resistance."	7.83	An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells. ( Dong, X; Han, P; Jiang, H; Jiang, X; Qiao, H; Sun, X; Tan, G; Tang, S; Zhai, B, 2016)
"Sorafenib, which has been used extensively for the treatment of renal cell cancer and advanced hepatocellular carcinoma (HCC), has also been shown to have antifibrotic effects in liver fibrosis."	7.83	Sorafenib Inhibits Renal Fibrosis Induced by Unilateral Ureteral Obstruction via Inhibition of Macrophage Infiltration. ( He, C; Li, Q; Liu, C; Liu, Q; Ma, W; Tao, L; Wang, X; Xue, D; Zhang, J; Zhang, W, 2016)
"Sorafenib, a multi-tyrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC)."	7.81	Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma. ( Li, H; Liang, Q; Liu, B; Ma, Y; Mei, X; Wang, Y, 2015)
"Eight-week-old rats were subjected to unilateral ureteral obstruction (UUO) and were intragastrically administered sorafenib, while control and sham groups were administered vehicle for 14 or 21 days."	7.81	Sorafenib ameliorates renal fibrosis through inhibition of TGF-β-induced epithelial-mesenchymal transition. ( Chen, Z; Duan, Z; Fu, R; Ge, H; Gui, B; Han, J; Jia, L; Ma, X; Ou, Y; Tian, L; Wang, L, 2015)
"Resveratrol improves insulin sensitivity and lowers hepatic glucose production (HGP) in rat models of obesity and diabetes, but the underlying mechanisms for these antidiabetic effects remain elusive."	7.81	Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network. ( Baur, JA; Breen, DM; Côté, CD; Daljeet, M; Duca, FA; Filippi, BM; Lam, TK; Rasmussen, BA; Zadeh-Tahmasebi, M, 2015)
"Sorafenib is a new standard treatment for patients with advanced hepatocellular carcinoma (HCC)."	7.81	Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice. ( Cheng, BY; Ching, RH; Lau, EY; Lee, TK; Lo, J; Ma, MK; Ng, IO, 2015)
"Sorafenib is a strong multikinase inhibitor targeting 2 different pathways of endometriosis pathogenesis: RAF kinase and vascular endothelial growth factor receptor (VEGFR)."	7.81	Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis. ( Batteux, F; Cerles, O; Chapron, C; Chouzenoux, S; Dousset, B; Leconte, M; Marcellin, L; Santulli, P, 2015)
"Mice treated with sorafenib or vehicle for 3 weeks underwent induced myocardial infarction (MI) after 1 week of treatment."	7.80	Sorafenib cardiotoxicity increases mortality after myocardial infarction. ( Barbe, M; Berretta, RM; Dunn, J; Duran, JM; Force, T; Gao, E; Gross, P; Houser, SR; Husain, S; Kubo, H; Lal, H; Makarewich, CA; Sharp, TE; Starosta, T; Trappanese, D; Vagnozzi, RJ; Yu, D, 2014)
"The immune modulatory drug lenalidomide has shown promising anti-tumor activity in a clinical trial of patients with advanced hepatocellular carcinoma (HCC)."	7.80	Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma. ( Chang, CJ; Cheng, AL; Gandhi, AK; Hsu, C; Huang, ZM; Jeng, YM; Liao, SC; Lin, YJ; Lin, ZZ; Ou, DL, 2014)
"To investigate the therapeutic effect of the hepatic arterial administration of sorafenib in rabbit VX-2 hepatocellular carcinoma (HCC) model."	7.80	Hepatic arterial administration of sorafenib and iodized oil effectively attenuates tumor growth and intrahepatic metastasis in rabbit VX2 hepatocellular carcinoma model. ( Duan, F; Fan, QS; Fu, JX; Liu, FY; Wang, MQ; Zhang, L, 2014)
"Sorafenib, a multi-tyrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC)."	7.79	Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma. ( Bu, Y; Chai, ZT; Jia, QA; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, M; Wang, WQ; Wu, WZ; Zhang, KZ; Zhang, QB; Zhu, XD, 2013)
"We previously demonstrated the pro-metastasis effect of sorafenib in hepatocellular carcinoma (HCC), which is mediated by down-regulation of tumor suppressor HTATIP2."	7.79	Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma. ( Ao, JY; Chai, ZT; Kong, LQ; Li, JQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Zhang, KZ; Zhang, QB; Zhang, W; Zhang, YY; Zhu, XD, 2013)
"To evaluate the effect of orally administered sorafenib on corneal neovascularization in rat models."	7.78	Inhibition of corneal neovascularization in rats by systemic administration of sorafenib. ( Choi, JS; Chung, SH; Joo, CK; Seo, JW, 2012)
"Antiangiogenic agents can sometimes promote tumor invasiveness and metastasis, but little is known about the effects of the antiangiogenic drug sorafenib on progression of hepatocellular carcinoma (HCC)."	7.78	Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice. ( Kong, LQ; Li, Q; Song, TQ; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Xiong, YQ; Xu, HX; Zhang, QB; Zhang, W; Zhu, XD; Zhuang, PY, 2012)
"Previously we reported that Akt inactivation determines the sensitivity of hepatocellular carcinoma (HCC) cells to bortezomib."	7.76	Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. ( Chen, KF; Chen, PJ; Cheng, AL; Lee, SS; Liu, TH; Yu, HC, 2010)
"Comparative hemodynamic effects of nicorandil (NCR), nitroglycerin (NTG) and cromakalim (CRM) were examined in a canine model of acute congestive heart failure (CHF)."	7.70	Beneficial hemodynamic effects of nicorandil in a canine model of acute congestive heart failure: comparison with nitroglycerin and cromakalim. ( Koyama, T; Matsuzaki, T; Nakasone, J; Noguchi, K; Ojiri, Y; Sakanashi, M, 1998)
"The present study investigates synergistic effects of the TNF-alpha inhibitor thalidomide and the poly(ADP-ribose) polymerase (PARP)-inhibitor nicotinic acid amide (NAA) in male DBA/1 hybird mice suffering from type II collagen-induced arthritis."	7.69	Synergistic effects of thalidomide and poly (ADP-ribose) polymerase inhibition on type II collagen-induced arthritis in mice. ( Dietrich, A; Kröger, H; Miesel, R; Ockenfels, H; Ohde, M; Rajnavölgyi, E, 1996)
" Here we assessed CBD dose-response effects in the Genetically Epilepsy Prone Rats (GEPR-3) strain, which exhibits two types of epileptic seizures, brainstem-dependent generalized tonic-clonic seizures and limbic seizures."	5.91	Cannabidiol attenuates generalized tonic-clonic and suppresses limbic seizures in the genetically epilepsy-prone rats (GEPR-3) strain. ( Campos-Rodriguez, C; Forcelli, PA; Garcia-Cairasco, N; Lazarini-Lopes, W; N'Gouemo, P, 2023)
"Oxytocin (OT) is a critical molecule for social recognition and memory that mediates social and emotional behaviours."	5.56	Nicotinamide riboside supplementation corrects deficits in oxytocin, sociability and anxiety of CD157 mutants in a mouse model of autism spectrum disorder. ( Brenner, C; Cherepanov, SM; Furuhara, K; Gerasimenko, M; Higashida, H; Ishihara, K; Lopatina, O; Salmina, AB; Shabalova, AA; Tsuji, C; Yokoyama, S, 2020)
"Treatment with liraglutide-restored animals' body weight, normalized blood glucose, decreased glycated hemoglobin, and increased insulin levels."	5.48	Liraglutide ameliorated peripheral neuropathy in diabetic rats: Involvement of oxidative stress, inflammation and extracellular matrix remodeling. ( Abdelkader, NF; El Awdan, SA; El-Shabrawy, OA; Moustafa, PE; Zaki, HF, 2018)
"Sorafenib is a potent drug for advanced HCC with multikinase inhibition activity."	5.43	Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model. ( Axelrod, JH; Divon, MS; Galun, E; Lanton, T; Peretz, T; Salmon, A; Sonnenblick, A; Zahavi, T, 2016)
" These data suggest that administration of NMN at a proper dosage has a strong protective effect against ischemic brain injury."	5.43	Nicotinamide mononucleotide inhibits post-ischemic NAD(+) degradation and dramatically ameliorates brain damage following global cerebral ischemia. ( Kristian, T; Long, A; Owens, K; Park, JH, 2016)
"Hepatocellular carcinoma is the fifth most common solid cancer worldwide."	5.40	SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma. ( Chen, IT; Chen, KF; Hsu, CY; Li, YS; Liu, CY; Shiau, CW; Su, JC; Tai, WT; Tseng, PH; Wu, SH, 2014)
"HPS (hepatopulmonary syndrome) is characterized by oxygen desaturation in patients with chronic liver disease."	5.39	Sorafenib treatment improves hepatopulmonary syndrome in rats with biliary cirrhosis. ( Chang, CC; Chuang, CL; Hsieh, HG; Hsu, SJ; Huang, HC; Lee, FY; Lee, SD; Lin, HC; Teng, TH; Wang, SS, 2013)
"Mcl-1, a survival factor in multiple myeloma, is downregulated at the protein level by sorafenib allowing for the execution of cell death, as ectopic overexpression of this protein protects multiple myeloma cells."	5.38	Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model. ( Björkholm, M; Celsing, F; De Raeve, H; Fristedt, C; Grandér, D; Gruber, A; Jernberg-Wiklund, H; Johnsson, P; Kharaziha, P; Kokaraki, G; Laane, E; Li, Q; Osterborg, A; Panaretakis, T; Panzar, M; Vanderkerken, K; Zhivotovsky, B, 2012)
"Surgical resection is the first-line treatment for hepatocellular carcinoma (HCC) patients with well-preserved liver function."	5.37	Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. ( Cheng, SQ; Deng, YZ; Feng, YX; Guan, DX; Li, JJ; Li, N; Qin, Y; Wang, H; Wang, HY; Wang, T; Wang, XF; Wu, MC; Xie, D; Yang, P; Yao, F; Zhu, YQ, 2011)
"Sorafenib treatment (daily gavage, 2."	5.35	Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. ( Desai, AA; Garcia, JG; Gomberg-Maitland, M; Husain, AN; Lang, RM; Liu, Y; Lussier, YA; Maitland, ML; Moreno-Vinasco, L; Ratain, MJ; Sam, L; Sammani, S; Singleton, PA, 2008)
" The likely involvement of the kinase pathway is implicated in the unique effects of nicotinamide riboside in raising tissue NAD concentrations in rodents and for potent effects in eliciting insulin sensitivity, mitochondrial biogenesis, and enhancement of sirtuin functions."	4.89	Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotection. ( Chi, Y; Sauve, AA, 2013)
" This study assessed corneal and somatic hypersensitivity in male rats treated with paclitaxel and whether it was relieved by nicotinamide riboside (NR)."	4.12	Nicotinamide Riboside Alleviates Corneal and Somatic Hypersensitivity Induced by Paclitaxel in Male Rats. ( Aicher, SA; Blum, C; Hamity, MV; Hammond, DL; Hegarty, DM; Kolker, SJ; Langmack, L, 2022)
"In this study, we aim to verify whether swim training can improve lactate metabolism, NAD+ and NADH levels, as well as modify the activity of glycolytic and NADH shuttle enzymes and monocarboxylate transporters (MCTs) in skeletal muscle of amyotrophic lateral sclerosis (ALS) mice."	4.12	Swim Training Affects on Muscle Lactate Metabolism, Nicotinamide Adenine Dinucleotides Concentration, and the Activity of NADH Shuttle Enzymes in a Mouse Model of Amyotrophic Lateral Sclerosis. ( Antosiewicz, J; Cieminski, K; Dzik, KP; Flis, DJ; Kaczor, JJ; Wieckowski, MR; Ziolkowski, W, 2022)
"The current work aimed to examine the properties of oral supplementation of niacinamide and undenatured type II collagen (UCII) on the inflammation and joint pain behavior of rats with osteoarthritis (OA)."	4.02	Niacinamide and undenatured type II collagen modulates the inflammatory response in rats with monoiodoacetate-induced osteoarthritis. ( Durmus, AS; Juturu, V; Kucuk, O; Orhan, C; Ozercan, IH; Sahin, K; Sahin, N; Tuzcu, M, 2021)
"The data show that nicotinamide riboside, the most energy-efficient among NAD precursors, could be useful for treatment of heart failure, notably in the context of DCM, a disease with few therapeutic options."	3.88	Nicotinamide Riboside Preserves Cardiac Function in a Mouse Model of Dilated Cardiomyopathy. ( Baczkó, I; Blanc, J; Brenner, C; Breton, M; Decaux, JF; Deloux, R; Diguet, N; Garnier, A; Gouge, A; Gressette, M; Lavery, GG; Li, Z; Manoury, B; Mericskay, M; Mougenot, N; Piquereau, J; Tannous, C; Trammell, SAJ; Zoll, J, 2018)
" In this study, we demonstrated that IL-10-producing macrophages contribute to immune tolerance in the inflamed liver under intestinal barrier disruption in a murine tandem model of dextran sulfate sodium (DSS) colitis and concanavalin A (Con A) hepatitis."	3.88	Intestinal barrier regulates immune responses in the liver via IL-10-producing macrophages. ( Amiya, T; Chu, PS; Ebinuma, H; Fukuda, S; Kanai, T; Katayama, T; Mikami, Y; Miyake, R; Nakamoto, N; Shiba, S; Suzuki, T; Taniki, N; Teratani, T; Tsukimi, T; Yamaguchi, A, 2018)
" Independent actions of the model drugs DNA-intercalating doxorubicin, RNA-interfering miR-34a and protein-inhibiting sorafenib on DNA replication, RNA translation and protein kinase signaling in highly metastatic, human osteosarcoma 143B cells were demonstrated by the increase of γH2A."	3.85	Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. ( DeVere White, RW; Duan, Z; Ho, PY; Jian, C; Lam, KS; Lara, PN; Qiu, JX; Tu, MJ; Wun, T; Yu, AM; Yu, AX; Zhang, Q, 2017)
"Sorafenib is the only approved targeted drug for hepatocellular carcinoma (HCC), but its effect on patients' survival gain is limited and varies over a wide range depending on pathogenetic conditions."	3.85	Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. ( Cho, EJ; Cho, H; Cho, KH; Cho, SH; Choi, WM; Hwang, CY; Jang, JJ; Kim, CY; Kim, K; Kim, YJ; Lee, JH; Lee, KB; Park, SM; Suh, KS; Won, JK; Yoon, JH; Yu, SJ, 2017)
"In a mouse model of HCC, effects of sorafenib were determined by tumor size, RFA-induced necrosis area (triphenyltetrazolium chloride staining), microvascular density (MVD; 4',6-diamidino-2-phenylindole and anti-CD31 antibody staining), and tumor perfusion (magnetic resonance imaging)."	3.85	Advantage of sorafenib combined with radiofrequency ablation for treatment of hepatocellular carcinoma. ( Chen, J; Fang, H; Jiang, B; Kang, M; Tang, Z; Wu, Y; Ye, Q; Zhang, B, 2017)
"We previously showed that 1-methylnicotinamide (1-MNA) and its analog 1,4-dimethylpyridine (1,4-DMP) could inhibit the formation of lung metastases and enhance the efficacy of cyclophosphamide-based chemotherapy in the model of spontaneously metastasizing 4T1 mouse mammary gland tumors."	3.85	The effects of 1,4-dimethylpyridine in metastatic prostate cancer in mice. ( Chlopicki, S; Denslow, A; Gebicki, J; Maciejewska, M; Marcinek, A; Nowak, M; Switalska, M; Wietrzyk, J, 2017)
" Purpose To assess diagnostic values of intra-voxel incoherent motion (IVIM) imaging in evaluating therapeutic effects of sorafenib on hepatocellular carcinoma (HCC) using mouse xenograft model."	3.85	Intravoxel incoherent motion MRI for monitoring the therapeutic response of hepatocellular carcinoma to sorafenib treatment in mouse xenograft tumor models. ( Cheong, H; Hong, SM; Kim, N; Lee, CK; Lee, SS; Lee, Y; Son, WC, 2017)
"We have previously demonstrated that isocorydine (ICD) can be served as a potential antitumor agent in hepatocellular carcinoma (HCC)."	3.83	Derivate isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/M cell cycle arrest and apoptosis. ( Chen, L; Ge, C; Li, H; Li, J; Li, M; Liu, J; Tian, H; Wang, T; Yao, M; Zhang, L; Zhao, F, 2016)
"The anti-angiogenic Sorafenib is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC)."	3.83	Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma. ( Bar-Zion, A; Butz, H; Daley, F; Foster, FS; Kerbel, RS; Kuczynski, EA; Lee, CR; Man, S; Reynolds, AR; Vermeulen, PB; Yin, M; Yousef, GM, 2016)
" A 5 d treatment of epileptic mice with systemic injections of the centrally available, potent, and specific P2X7 receptor antagonist JNJ-47965567 (30 mg/kg) significantly reduced spontaneous seizures during continuous video-EEG monitoring that persisted beyond the time of drug presence in the brain."	3.83	Transient P2X7 Receptor Antagonism Produces Lasting Reductions in Spontaneous Seizures and Gliosis in Experimental Temporal Lobe Epilepsy. ( Alves, M; Arribas-Blázquez, M; Artalejo, AR; Bhattacharya, A; Conroy, RM; Delanty, N; Diaz-Hernandez, M; Engel, T; Farrell, MA; Henshall, DC; Jimenez-Pacheco, A; Letavic, M; Miras-Portugal, MT; O'Brien, DF; Olivos-Oré, LA; Sanz-Rodriguez, A, 2016)
"Sorafenib resistance remains a major obstacle for the effective treatment of hepatocellular carcinoma (HCC), and a number of miRNAs contribute to this resistance."	3.83	An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells. ( Dong, X; Han, P; Jiang, H; Jiang, X; Qiao, H; Sun, X; Tan, G; Tang, S; Zhai, B, 2016)
"Sorafenib, which has been used extensively for the treatment of renal cell cancer and advanced hepatocellular carcinoma (HCC), has also been shown to have antifibrotic effects in liver fibrosis."	3.83	Sorafenib Inhibits Renal Fibrosis Induced by Unilateral Ureteral Obstruction via Inhibition of Macrophage Infiltration. ( He, C; Li, Q; Liu, C; Liu, Q; Ma, W; Tao, L; Wang, X; Xue, D; Zhang, J; Zhang, W, 2016)
"Sorafenib, a multi-tyrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC)."	3.81	Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma. ( Li, H; Liang, Q; Liu, B; Ma, Y; Mei, X; Wang, Y, 2015)
"Eight-week-old rats were subjected to unilateral ureteral obstruction (UUO) and were intragastrically administered sorafenib, while control and sham groups were administered vehicle for 14 or 21 days."	3.81	Sorafenib ameliorates renal fibrosis through inhibition of TGF-β-induced epithelial-mesenchymal transition. ( Chen, Z; Duan, Z; Fu, R; Ge, H; Gui, B; Han, J; Jia, L; Ma, X; Ou, Y; Tian, L; Wang, L, 2015)
"Resveratrol improves insulin sensitivity and lowers hepatic glucose production (HGP) in rat models of obesity and diabetes, but the underlying mechanisms for these antidiabetic effects remain elusive."	3.81	Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network. ( Baur, JA; Breen, DM; Côté, CD; Daljeet, M; Duca, FA; Filippi, BM; Lam, TK; Rasmussen, BA; Zadeh-Tahmasebi, M, 2015)
"Sorafenib is a new standard treatment for patients with advanced hepatocellular carcinoma (HCC)."	3.81	Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice. ( Cheng, BY; Ching, RH; Lau, EY; Lee, TK; Lo, J; Ma, MK; Ng, IO, 2015)
"Sorafenib is a strong multikinase inhibitor targeting 2 different pathways of endometriosis pathogenesis: RAF kinase and vascular endothelial growth factor receptor (VEGFR)."	3.81	Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis. ( Batteux, F; Cerles, O; Chapron, C; Chouzenoux, S; Dousset, B; Leconte, M; Marcellin, L; Santulli, P, 2015)
"Sorafenib--a broad kinase inhibitor--is a standard therapy for advanced hepatocellular carcinoma (HCC) and has been shown to exert antifibrotic effects in liver cirrhosis, a precursor of HCC."	3.80	Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. ( Chen, Y; Duda, DG; Duyverman, AM; Hiddingh, L; Huang, P; Huang, Y; Jain, RK; Koppel, C; Lauwers, GY; Reiberger, T; Roberge, S; Samuel, R; Zhu, AX, 2014)
"These findings suggest that MPT0E028 in combination with sorafenib has significant anti-hepatocellular carcinoma activity in preclinical models, potentially suggesting a novel therapeutic strategy for patients with advanced hepatocellular carcinoma."	3.80	Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo. ( Chen, CH; Chen, CS; Chen, MC; Liou, JP; Pan, SL; Teng, CM; Tsai, AC; Wang, JC, 2014)
"Mice treated with sorafenib or vehicle for 3 weeks underwent induced myocardial infarction (MI) after 1 week of treatment."	3.80	Sorafenib cardiotoxicity increases mortality after myocardial infarction. ( Barbe, M; Berretta, RM; Dunn, J; Duran, JM; Force, T; Gao, E; Gross, P; Houser, SR; Husain, S; Kubo, H; Lal, H; Makarewich, CA; Sharp, TE; Starosta, T; Trappanese, D; Vagnozzi, RJ; Yu, D, 2014)
"The immune modulatory drug lenalidomide has shown promising anti-tumor activity in a clinical trial of patients with advanced hepatocellular carcinoma (HCC)."	3.80	Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma. ( Chang, CJ; Cheng, AL; Gandhi, AK; Hsu, C; Huang, ZM; Jeng, YM; Liao, SC; Lin, YJ; Lin, ZZ; Ou, DL, 2014)
"To investigate the therapeutic effect of the hepatic arterial administration of sorafenib in rabbit VX-2 hepatocellular carcinoma (HCC) model."	3.80	Hepatic arterial administration of sorafenib and iodized oil effectively attenuates tumor growth and intrahepatic metastasis in rabbit VX2 hepatocellular carcinoma model. ( Duan, F; Fan, QS; Fu, JX; Liu, FY; Wang, MQ; Zhang, L, 2014)
"Sorafenib, a multi-tyrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC)."	3.79	Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma. ( Bu, Y; Chai, ZT; Jia, QA; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, M; Wang, WQ; Wu, WZ; Zhang, KZ; Zhang, QB; Zhu, XD, 2013)
"We previously demonstrated the pro-metastasis effect of sorafenib in hepatocellular carcinoma (HCC), which is mediated by down-regulation of tumor suppressor HTATIP2."	3.79	Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma. ( Ao, JY; Chai, ZT; Kong, LQ; Li, JQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Zhang, KZ; Zhang, QB; Zhang, W; Zhang, YY; Zhu, XD, 2013)
"We tested the hypothesis that recombinant human VEGF-A165b and the serine arginine protein kinase (SRPK) inhibitor, SRPIN340, which controls splicing of the VEGF-A pre-mRNA, prevent neovascularization in a rodent model of retinopathy of prematurity (ROP)."	3.79	SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity. ( Bates, DO; Dick, AD; Gammons, MV; Harper, SJ, 2013)
" In this study, we evaluated the role of synthetic dsRNA as a TLR3 synergist and by combining with sorafenib in anti-hepatocellular carcinoma (HCC) in vitro and in vivo."	3.79	A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo. ( Chen, L; Qin, J; Wang, GL; Wei, YZ; Xu, YY; Zhang, YX; Zhou, JM; Zhu, YY, 2013)
"To evaluate the effect of orally administered sorafenib on corneal neovascularization in rat models."	3.78	Inhibition of corneal neovascularization in rats by systemic administration of sorafenib. ( Choi, JS; Chung, SH; Joo, CK; Seo, JW, 2012)
"Antiangiogenic agents can sometimes promote tumor invasiveness and metastasis, but little is known about the effects of the antiangiogenic drug sorafenib on progression of hepatocellular carcinoma (HCC)."	3.78	Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice. ( Kong, LQ; Li, Q; Song, TQ; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Xiong, YQ; Xu, HX; Zhang, QB; Zhang, W; Zhu, XD; Zhuang, PY, 2012)
"Previously we reported that Akt inactivation determines the sensitivity of hepatocellular carcinoma (HCC) cells to bortezomib."	3.76	Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. ( Chen, KF; Chen, PJ; Cheng, AL; Lee, SS; Liu, TH; Yu, HC, 2010)
"The human tubercle bacillus Mycobacterium tuberculosis can synthesize NAD(+) using the de novo biosynthesis pathway or the salvage pathway."	3.76	NAD+ auxotrophy is bacteriocidal for the tubercle bacilli. ( Chen, B; Jacobs, WR; Vilchèze, C; Weinrick, B; Wong, KW, 2010)
"Dextran sodium sulphate (DSS)-treated mice and piroxicam-treated IL-10-/- mice were used as animal models of colitis."	3.74	Blockade of adenosine A2B receptors ameliorates murine colitis. ( Figler, H; Figler, R; Gewirtz, A; Kolachala, V; Linden, J; Merlin, D; Mwangi, S; Ruble, B; Sitaraman, S; Srinivasan, S; Vijay-Kumar, M; Wang, L, 2008)
"Migration of HUVEC cells, the ability of HUVEC cells to form tubes, and proliferative capacity of a human ocular melanoma cell line were tested in the presence of lenalidomide and sorafenib alone and in combination."	3.74	Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. ( Blansfield, JA; Kachala, S; Libutti, SK; Lorang, D; Mangiameli, DP; Muller, GW; Schafer, PH; Stirling, DI, 2007)
" Administration of resveratrol suppressed AT1R expression in the mouse aorta and blunted angiotensin II-induced hypertension."	3.74	SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression in vascular smooth muscle cells. ( Hashimoto, T; Ichiki, T; Imayama, I; Inanaga, K; Miyazaki, R; Sadoshima, J; Sunagawa, K, 2008)
"Comparative hemodynamic effects of nicorandil (NCR), nitroglycerin (NTG) and cromakalim (CRM) were examined in a canine model of acute congestive heart failure (CHF)."	3.70	Beneficial hemodynamic effects of nicorandil in a canine model of acute congestive heart failure: comparison with nitroglycerin and cromakalim. ( Koyama, T; Matsuzaki, T; Nakasone, J; Noguchi, K; Ojiri, Y; Sakanashi, M, 1998)
" In vivo treatment with ip administration of 3-aminobenzamide (10 mg/kg, 1 and 6 hrs after zymosan injection) or nicotinamide (50 mg/kg, 1 and 6 hrs after zymosan injection) significantly decreased mortality, inhibited the development of peritonitis, and reduced peroxynitrite formation."	3.70	Protective effect of poly(ADP-ribose) synthetase inhibition on multiple organ failure after zymosan-induced peritonitis in the rat. ( Caputi, AP; Costantino, G; Cuzzocrea, S; Sottile, A; Teti, D; Zingarelli, B, 1999)
"The present study investigates synergistic effects of the TNF-alpha inhibitor thalidomide and the poly(ADP-ribose) polymerase (PARP)-inhibitor nicotinic acid amide (NAA) in male DBA/1 hybird mice suffering from type II collagen-induced arthritis."	3.69	Synergistic effects of thalidomide and poly (ADP-ribose) polymerase inhibition on type II collagen-induced arthritis in mice. ( Dietrich, A; Kröger, H; Miesel, R; Ockenfels, H; Ohde, M; Rajnavölgyi, E, 1996)
"Subcutaneous tumours and artificially induced pulmonary metastases of the rhabdomyosarcoma R1H of the rat were treated either with fractionated irradiation alone or in combination with nicotinamide and carbogen."	3.69	Combination of fractionated irradiation with nicotinamide and carbogen in R1H-tumours of the rat and its pulmonary metastases. ( Beck-Bornholdt, HP; Krüll, A; Raabe, A; Rett, M, 1997)
" Angina pectoris was induced by methacholine or isoproterenol, and the change in the ST-segments in the electrocardiogram (ECG) was used as the parameter to indicate angina pectoris."	3.68	Effect of KRN2391, a novel vasodilator, on various experimental anginal models in rats. ( Fukata, Y; Fukushima, H; Harada, K; Kaneta, S; Miwa, A; Ogawa, N, 1993)
"The relationship between the dose of intravenously administered streptozotocin (a N-nitroso derivative of glucosamine) and the diabetogenic response has been explored by use of the following indices of diabetogenic action: serum glucose, urine volume, and glycosuria, ketonuria, serum immunoreactive insulin (IRI), and pancreatic IRI content."	3.65	Diabetogenic action of streptozotocin: relationship of dose to metabolic response. ( Junod, A; Lambert, AE; Renold, AE; Stauffacher, W, 1969)
"Nicotinamide prevents autoimmune diabetes in animal models, possibly through inhibition of the DNA repair enzyme poly-ADP-ribose polymerase and prevention of beta-cell NAD depletion."	2.71	European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. ( Bingley, PJ; Collier, T; Emmett, CL; Gale, EA, 2004)
"The study of xeroderma pigmentosum has yielded unforeseen advances regarding how defects in the nucleotide excision repair pathway result in this devastating disease, but development of therapeutic strategies has trailed behind the mechanistic discoveries."	2.61	Novel therapeutic approaches to xeroderma pigmentosum. ( Glass, DA; Weon, JL, 2019)
"Up to 8% of pregnant women suffer from preeclampsia (PE), a deadly disease characterized by high blood pressure (BP), blood vessel damage, called endotheliosis (vascular endothelial swelling with narrowing of capillary lumen), and high levels of protein in the urine."	2.58	Vitamin B ( Fushima, T; Ito, S; Li, F; Oe, Y; Oyanagi, G; Saigusa, D; Sato, E; Sato, H; Sekimoto, A; Takahashi, N, 2018)
" We detected a moderate dose-response in one clinically approved indication, hepatocellular carcinoma, but not in another approved malignancy, renal cell carcinoma, or when data were pooled across all malignancies tested."	2.53	Design and Reporting of Targeted Anticancer Preclinical Studies: A Meta-Analysis of Animal Studies Investigating Sorafenib Antitumor Efficacy. ( Fergusson, D; Henderson, VC; Kimmelman, J; MacKinnon, N; Mattina, J, 2016)
"The marked heterogeneity of hepatocellular carcinoma (HCC), particularly with regard to the etiology and severity of the underlying cirrhosis, makes clinical trial design in this disease very challenging."	2.46	Developing better treatments in hepatocellular carcinoma. ( Duffy, A; Greten, T, 2010)
"Rosacea is one of the most common dermatoses of adults."	2.45	[Rosacea 2009 : new advances in pathophysiology, clinical staging and therapeutic strategies]. ( Lehmann, P; Sobottka, A, 2009)
" Here we assessed CBD dose-response effects in the Genetically Epilepsy Prone Rats (GEPR-3) strain, which exhibits two types of epileptic seizures, brainstem-dependent generalized tonic-clonic seizures and limbic seizures."	1.91	Cannabidiol attenuates generalized tonic-clonic and suppresses limbic seizures in the genetically epilepsy-prone rats (GEPR-3) strain. ( Campos-Rodriguez, C; Forcelli, PA; Garcia-Cairasco, N; Lazarini-Lopes, W; N'Gouemo, P, 2023)
"In a mouse model of cardiac arrest, 100 mg/kg NAM administered IV immediately after cardiopulmonary resuscitation resulted in 100% survival at 4 h as compared to 50% in the saline group."	1.91	Nicotinamide restores tissue NAD+ and improves survival in rodent models of cardiac arrest. ( Gasior, FM; Justice, CN; Lee, C; Li, J; Lin, S; O'Donnell, JM; Vanden Hoek, TL; Wang, H; Zhu, X, 2023)
"All elevated bone formation and bone resorption markers were decreased with peficitinib but only partially decreased with etanercept."	1.72	Peficitinib improves bone fragility by recovering bone turnover imbalance in arthritic mice. ( Emori, T; Fujii, Y; Hanaoka, K; Nakamura, Y; Nakano, M; Sugahara, S; Suzuki, T; Takahashi, J; Takeshita, N, 2022)
"Acute lung injury is an important factor that leads to the death of patients with pneumonia."	1.62	The mechanism of nicotinamide on reducing acute lung injury by inhibiting MAPK and NF-κB signal pathway. ( Li, J; Xu, Y; Zhang, Q; Zhong, H, 2021)
"Depression is one of the most common psychiatric disorders, and there is strong demand for developing novel antidepressants with better efficacy and less adverse effects."	1.62	Antidepressant-like effects of 1-methylnicotinamide in a chronic unpredictable mild stress model of depression. ( Gu, JH; Ji, CH; Jiang, B; Liu, Y; Tang, WQ; Zhang, Y; Zhao, J, 2021)
"Colitis was induced in C57BL/6 male mice by administration of 1."	1.62	Nicotinamide Ameliorates Dextran Sulfate Sodium-Induced Chronic Colitis in Mice through Its Anti-Inflammatory Properties and Modulates the Gut Microbiota. ( Chang, B; Kang, K; Pan, D; Sang, LX; Sun, Y, 2021)
"Glaucoma is a common neurodegenerative disease in which neuronal levels of NAD decline."	1.62	Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction. ( Brautaset, R; Burgess, RW; Cimaglia, G; Crowston, JG; Domínguez-Vicent, A; Ellis, SA; Fuerst, PG; Jöe, M; Jóhannesson, G; Kokkali, E; Kolko, M; Lardner, E; Morgan, JE; Otmani, A; Rho, S; Sun, S; Tribble, JR; Venkataraman, AP; Vohra, R; Votruba, M; Williams, PA, 2021)
"Familial forms of Alzheimer's disease associated with the accumulation of a toxic form of amyloid-β (Aβ) peptides are linked to mitochondrial impairment."	1.62	Parp mutations protect from mitochondrial toxicity in Alzheimer's disease. ( Celardo, I; Fedele, G; Loh, SHY; Martins, LM; Yu, Y, 2021)
" In this study, zebrafish served as an animal model to investigate the toxic effects and mechanisms of boscalid on aquatic vertebrates or higher animals."	1.56	Characterization of boscalid-induced oxidative stress and neurodevelopmental toxicity in zebrafish embryos. ( Cao, Z; Liao, X; Liu, F; Lu, H; Meng, Y; Meng, Z; Su, M; Wang, H; Zhang, S; Zhou, L, 2020)
"Oxytocin (OT) is a critical molecule for social recognition and memory that mediates social and emotional behaviours."	1.56	Nicotinamide riboside supplementation corrects deficits in oxytocin, sociability and anxiety of CD157 mutants in a mouse model of autism spectrum disorder. ( Brenner, C; Cherepanov, SM; Furuhara, K; Gerasimenko, M; Higashida, H; Ishihara, K; Lopatina, O; Salmina, AB; Shabalova, AA; Tsuji, C; Yokoyama, S, 2020)
"Chronic alcohol abuse is common and a leading cause of alcoholic liver disease (ALD)."	1.56	Adult zebrafish as an in vivo drug testing model for ethanol induced acute hepatic injury. ( Kim, SH; Park, KH, 2020)
"SRT1720 treatment increased the protein levels of occludin and ZO-1 and inhibited Caco-2 apoptosis, whereas NAM administration caused the opposite effects."	1.51	Sirtuin 1 alleviates endoplasmic reticulum stress-mediated apoptosis of intestinal epithelial cells in ulcerative colitis. ( Ding, CY; Gu, ML; Ji, F; Pan, HH; Ren, MT; Yu, MS; Zhou, XX, 2019)
" The solubility, dissolution rate and bioavailability of gliclazide SGNCs were significantly improved compared to pure gliclazide."	1.51	Fabrication of Second Generation Smarter PLGA Based Nanocrystal Carriers for Improvement of Drug Delivery and Therapeutic Efficacy of Gliclazide in Type-2 Diabetes Rat Model. ( Bhattamisra, SK; Krishnamoorthy, R; Panda, BP; Patnaik, S; Seng, LB; Shivashekaregowda, NKH, 2019)
"The major adverse effect associated with systemic administration of Fluconazole (FLZ), is hepatic toxicity."	1.51	Vitamin B combination reduces fluconazole toxicity in Wistar rats. ( Al-Abbasi, FA; Anwar, F; Mushtaq, G; Sadath, S, 2019)
"Renal interstitial fibrosis is a common pathological feature in progressive kidney diseases currently lacking effective treatment."	1.51	Nicotinamide reduces renal interstitial fibrosis by suppressing tubular injury and inflammation. ( Cai, J; Dong, Z; Liu, Z; Shu, S; Tang, C; Wang, Y; Zheng, M, 2019)
"Hyperglycemia was induced in rats by the administration of nicotinamide and streptozotocin."	1.51	Intravenous delivery of adipose tissue-derived mesenchymal stem cells improves brain repair in hyperglycemic stroke rats. ( Detante, O; Diekhorst, L; Díez-Tejedor, E; Fuentes, B; Gómez-de Frutos, MC; Gutiérrez-Fernández, M; Jolkkonen, J; Laso-García, F; Martínez-Arroyo, A; Moisan, A; Otero-Ortega, L, 2019)
"Strategies to correct hypoxemia have the potential to improve clinical outcomes in ARDS."	1.48	GBT1118, a compound that increases the oxygen affinity of hemoglobin, improves survival in murine hypoxic acute lung injury. ( Bastarache, JA; Dufu, K; Hutchaleelaha, A; Lehrer-Graiwer, J; Li, CM; Majka, SM; Putz, ND; Shaver, CM; Ware, LB; Xu, Q, 2018)
"Treatment with liraglutide-restored animals' body weight, normalized blood glucose, decreased glycated hemoglobin, and increased insulin levels."	1.48	Liraglutide ameliorated peripheral neuropathy in diabetic rats: Involvement of oxidative stress, inflammation and extracellular matrix remodeling. ( Abdelkader, NF; El Awdan, SA; El-Shabrawy, OA; Moustafa, PE; Zaki, HF, 2018)
"Sepsis-caused multiple organ failure remains the major cause of morbidity and mortality in intensive care units."	1.48	Administration of nicotinamide riboside prevents oxidative stress and organ injury in sepsis. ( Fan, GC; Hong, G; Lu, Z; Ni, R; Peng, T; Wang, G; Zhang, L; Zheng, D, 2018)
"Myricitrin is a plant-derived antioxidant, and its solid lipid nanoparticle (SLN) may be more potent."	1.48	Solid Lipid Nanoparticles of Myricitrin Have Antioxidant and Antidiabetic Effects on Streptozotocin-Nicotinamide-Induced Diabetic Model and Myotube Cell of Male Mouse. ( Ahangarpour, A; Badavi, M; Khorsandi, L; Kouchak, M; Oroojan, AA, 2018)
"oral, in the early stage of Alzheimer's disease."	1.48	Nicotinamide loaded functionalized solid lipid nanoparticles improves cognition in Alzheimer's disease animal model by reducing Tau hyperphosphorylation. ( Akbari Javar, H; Amini, A; Baha'addini Beigi Zarandi, BF; Dinarvand, R; Montaseri, H; Vakilinezhad, MA, 2018)
"Alzheimer's disease is a common and devastating disease characterized by aggregation of the amyloid-β peptide."	1.46	Enhancing mitochondrial proteostasis reduces amyloid-β proteotoxicity. ( Auwerx, J; Beck, JS; Counts, SE; D'Amico, D; Mouchiroud, L; Moullan, N; Potenza, F; Rietsch, S; Romani, M; Schmid, AW; Sorrentino, V; Zhang, H, 2017)
"TGN-020 significantly reduced oedema, glial scar, albumin effusion, and apoptosis, at both 3 and 7 days after MCAO."	1.46	Inhibition of Aquaporin-4 Improves the Outcome of Ischaemic Stroke and Modulates Brain Paravascular Drainage Pathways. ( Balsanu, TA; Bogdan, C; Carare, RO; Divan, T; Margaritescu, C; Mogoanta, L; Muresanu, DF; Pirici, D; Pirici, I; Vitalie, V, 2017)
"Sorafenib (10 mg/kg) was given daily to rats orally for 2 weeks, started 6 weeks after DENA (200 mg/kg, single i."	1.46	Sorafenib effect on liver neoplastic changes in rats: more than a kinase inhibitor. ( Abd El-Fattah, EE; El-Ashmawy, NE; El-Bahrawy, HA; Khedr, EG, 2017)
" The goal of this study was to elucidate the antitumor effect of the flavonoid, fisetin, combined with the multikinase inhibitor, sorafenib, against human cervical cancer cells in vitro and in vivo."	1.43	Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway. ( Cheng, CW; Hsieh, YH; Lin, CL; Lin, MT; Lin, TY; Tsai, JP; Wu, CC; Yang, SF, 2016)
"Sorafenib is a potent drug for advanced HCC with multikinase inhibition activity."	1.43	Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model. ( Axelrod, JH; Divon, MS; Galun, E; Lanton, T; Peretz, T; Salmon, A; Sonnenblick, A; Zahavi, T, 2016)
"Sorafenib treatment had no effect on tumor growth in a 4T1 mouse model of breast cancer, but induced M2 macrophage polarization in tumors."	1.43	Inhibition of tumor growth and metastasis by photoimmunotherapy targeting tumor-associated macrophage in a sorafenib-resistant tumor model. ( Cai, Y; Gao, D; Gao, L; Jia, B; Lai, J; Liu, H; Liu, Z; Wang, F; Zhang, C, 2016)
"Cardiac hypertrophy is a major risk factor for heart failure."	1.43	Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib. ( Cantarella, D; Cimino, J; Comoglio, PM; Crepaldi, T; Fontani, L; Gallo, S; Gatti, S; Medico, E; Morello, M; Natale, M; Ponzetto, A; Sala, V; Vigna, E, 2016)
"ABSTACT Human hepatocellular carcinoma (HCC) is known to have a poor prognosis."	1.43	Iron depletion enhances the effect of sorafenib in hepatocarcinoma. ( Fujiwara, T; Kagawa, S; Katsube, R; Kimura, F; Matsukawa, A; Ninomiya, T; Noma, K; Nouso, K; Ohara, T; Shirakawa, Y; Tazawa, H; Tomono, Y; Urano, S; Yamamoto, K, 2016)
"Acetaminophen is a widely used analgesic and antipyretic agent, which is safe at therapeutic doses."	1.43	Role of nicotinamide (vitamin B3) in acetaminophen-induced changes in rat liver: Nicotinamide effect in acetaminophen-damged liver. ( Mahmoud, AA; Mahmoud, YI, 2016)
"Diabetic foot ulcer is a serious complication of diabetes, which affects a significant percentage (15%) of diabetics and up to 15%-24% of those affected may require amputation."	1.43	Evaluation of wound healing properties of bioactive aqueous fraction from Moringa oleifera Lam on experimentally induced diabetic animal model. ( Abas, F; Arulselvan, P; Cheah, PS; Fakurazi, S; Muhammad, AA, 2016)
" These data suggest that administration of NMN at a proper dosage has a strong protective effect against ischemic brain injury."	1.43	Nicotinamide mononucleotide inhibits post-ischemic NAD(+) degradation and dramatically ameliorates brain damage following global cerebral ischemia. ( Kristian, T; Long, A; Owens, K; Park, JH, 2016)
"Progression of pulmonary hypertension is associated with the activation of the NNMT-MNA pathway in rats and humans."	1.43	Activation of the nicotinamide N-methyltransferase (NNMT)-1-methylnicotinamide (MNA) pathway in pulmonary hypertension. ( Chlopicki, S; Fedorowicz, A; Jakubowski, A; Kopec, G; Kutryb-Zając, B; Mateuszuk, Ł; Skórka, T; Słomińska, E; Walczak, M; Zakrzewska, A; Łomnicka, M, 2016)
"Sorafenib treatment restored mitochondrial function and reduced collagen deposition by nearly 63% compared to the NASH group."	1.42	Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model. ( Barbeiro, DF; Bida, PM; Carrilho, FJ; Coelho, AM; Cogliati, B; D'Albuquerque, LA; Kubrusly, MS; Mazo, DF; Oliveira, CP; Pereira, IV; Souza, HP; Stefano, JT; Torres, MM; Xerfan, MP, 2015)
"Early diagnosis of malignant melanoma is important for patient survival."	1.42	Synthesis and evaluation of ¹²³/¹³¹I-Iochlonicotinamide as a novel SPECT probe for malignant melanoma. ( Chang, CC; Chang, CH; Chen, CL; Lin, MH; Liu, RS; Shen, CC; Wang, HE, 2015)
" Starting from compound 1, oral bioavailability was improved by modifying metabolically unstable sites and reducing molecular weight."	1.42	Orally active ghrelin receptor inverse agonists and their actions on a rat obesity model. ( Funami, H; Igawa, Y; Iwaki, T; Kamiide, Y; Kanki, S; Koyama, M; Maruoka, H; Muto, T; Nagahira, A; Shibata, M; Takahashi, B, 2015)
"Sorafenib treatments did not affect paw-withdrawal responses to non-noxious or to noxious mechanical stimuli."	1.42	A model of neuropathic pain induced by sorafenib in the rat: Effect of dimiracetam. ( Di Cesare Mannelli, L; Farina, C; Ghelardini, C; Maresca, M; Scherz, MW, 2015)
"The use of cytoflavin in the treatment of stroke was accompanied by the earlier and more intense activation of neurotrophic mechanisms in astrocytes, delayed activation of neurotrophic mechanisms in endothelial cells, which promoted neuroprotection in acute ischemic stroke."	1.42	[Characteristics of the regulation of neurotrophic mechanisms in ischemic stroke]. ( Gracheva, EV; Kovalenko, AL; Malkova, VM; Trashkov, AP; Tsygan, NV; Vasiliev, AG; Yakovleva, VA, 2015)
" Pharmacokinetic parameters of nicorandil and its isomers, as well as the plasma concentrations of the corresponding denitrated metabolites and also nicotinamide and nitrite were determined."	1.40	Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers. ( Almeida, MO; Araujo, DP; César, IC; Coelho, MM; de Fátima, A; Dutra, MM; Godin, AM; Machado, RR; Menezes, RR; Oliveira, FC; Pianetti, GA; Santos, DA; Santos, JR, 2014)
"Lung cancer is a heterogeneous disease encompassing a wide array of genetic abnormalities."	1.40	Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. ( Arif, Q; Hasina, R; Husain, AN; Kawada, I; Mueller, J; Salgia, R; Smithberger, E; Vokes, EE, 2014)
" donovani in the BALB/c mouse model of infection; dosing on days 7-11 with a 50 mg/kg oral dose of sunitinib, lapatinib or sorafenib reduced liver amastigote burdens by 41%, 36% and 30%, respectively, compared with untreated control mice."	1.40	Activity of anti-cancer protein kinase inhibitors against Leishmania spp. ( Croft, SL; Sanderson, L; Yardley, V, 2014)
"Colitis was induced in C57BL/6 mice either by oral infection with Citrobacter rodentium or by DSS (dextran sodium sulphate) administration, and animals were systemically treated with NAM."	1.40	Nicotinamide treatment ameliorates the course of experimental colitis mediated by enhanced neutrophil-specific antibacterial clearance. ( Berdel, WE; Bettenworth, D; Bokemeyer, C; Heidemann, J; Hengst, K; Kerstiens, L; Kyme, P; Nowacki, TM; Ross, M; Schwammbach, D; Thoennissen, GB; Thoennissen, NH, 2014)
"Mitochondrial disorders are highly heterogeneous conditions characterized by defects of the mitochondrial respiratory chain."	1.40	NAD(+)-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease. ( Auwerx, J; Cerutti, R; Dantzer, F; Lamperti, C; Leoni, V; Li, W; Marchet, S; Pirinen, E; Sauve, AA; Schon, EA; Viscomi, C; Zeviani, M, 2014)
"Sorafenib treatment led to transcriptional changes of Igf1, Id1, and cMet over time, which may reflect the emergence of potential escape mechanisms."	1.40	An inducible hepatocellular carcinoma model for preclinical evaluation of antiangiogenic therapy in adult mice. ( Arnold, B; Augustin, HG; Bergeest, JP; Géraud, C; Goerdt, S; Hu, J; Komljenovic, D; Mogler, C; Neumann, A; Rohr, K; Runge, A; Schirmacher, P; Wieland, M, 2014)
"Hepatocellular carcinoma is the fifth most common solid cancer worldwide."	1.40	SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma. ( Chen, IT; Chen, KF; Hsu, CY; Li, YS; Liu, CY; Shiau, CW; Su, JC; Tai, WT; Tseng, PH; Wu, SH, 2014)
"The disturbance of lipid metabolism was induced by the introduction of exogenic cholesterol-in -oil emulsion in dosage 40 mg /kg of body mass during 20 days."	1.40	[The assessment of the effects of cytoflavin and cardioxipin on the emotional status of rats with dyslipidemia]. ( Antropova, NV; Kustikova, IN; Moiseeva, IIa; Rodina, OP; Vodop'ianova, OA, 2014)
"FLT3(ITD) subtype acute myeloid leukemia (AML) has a poor prognosis with currently available therapies."	1.40	FLT3 and CDK4/6 inhibitors: signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia. ( D'Argenio, DZ; Hsu, CP; Huard, J; Kuchimanchi, M; Lu, JF; Ma, J; Sun, YN; Weidner, M; Xu, G; Xu, Y; Zhang, Y, 2014)
" Accumulating evidences show that chemotherapeutic drugs could act as immune supportive instead of immunosuppressive agents when proper dosage is used, and combined with immunotherapy often results in better treatment outcomes than monotherapy."	1.40	Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment. ( Chang, YF; Chuang, HY; Hwang, JJ; Liu, RS, 2014)
"Angiosarcoma is a rare neoplasm of endothelial origin that has limited treatment options and poor five-year survival."	1.39	Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma. ( Andersen, NJ; Baker, LH; Boguslawski, EA; Dawes, MJ; Duesbery, NS; Dykema, KJ; Froman, RE; Furge, KA; Kamstock, DA; Kitchell, BE; Krivochenitser, RI; Nickoloff, BJ; Thomas, DG, 2013)
" Previously, we reported on the development of LY2801653: a novel, orally bioavailable oncokinase inhibitor with MET as one of its targets."	1.39	Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET. ( Bi, C; Credille, KM; Donoho, GP; Manro, JR; Peek, VL; Walgren, RA; Wijsman, JA; Wu, W; Yan, L; Yan, SB, 2013)
"Sorafenib-treated mice showed a smaller increase in tumor size on day + 14 in comparison to vehicle-treated mice (tumor volume increase + 175 % vs."	1.39	Early prediction of treatment response to sorafenib with elastosonography in a mice xenograft model of hepatocellular carcinoma: a proof-of-concept study. ( Baron Toaldo, M; Bolondi, L; Cipone, M; Marinelli, S; Milazzo, M; Palamà, C; Piscaglia, F; Salvatore, V; Venerandi, L, 2013)
"Spinocerebellar ataxia type 1 (SCA1) is a genetic disorder characterized by severe ataxia associated with progressive loss of cerebellar Purkinje cells."	1.39	Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1. ( Battaglia, G; Biagioni, F; Bucci, D; Cannella, M; Fazio, F; Gradini, R; Lionetto, L; Mascio, G; Nicoletti, F; Notartomaso, S; Puliti, A; Scarselli, P; Signore, M; Simmaco, M; Weisz, F; Zappulla, C, 2013)
"Absence epilepsy is generated by the cortico-thalamo-cortical network, which undergoes a finely tuned regulation by metabotropic glutamate (mGlu) receptors."	1.39	Potentiation of mGlu5 receptors with the novel enhancer, VU0360172, reduces spontaneous absence seizures in WAG/Rij rats. ( Biagioni, F; Conn, PJ; D'Amore, V; Jones, CK; Lindsley, CW; Molinaro, G; Ngomba, RT; Nicoletti, F; Prete, A; Rodriguez, AL; Santolini, I; Stauffer, SR; van Luijtelaar, G; van Rijn, CM; Vinson, PN; Zhou, Y, 2013)
"Sorafenib is a multi-kinase inhibitor that blocks cell proliferation and angiogenesis."	1.39	Monitoring anti-angiogenic therapy in colorectal cancer murine model using dynamic contrast-enhanced MRI: comparing pixel-by-pixel with region of interest analysis. ( Fan, X; Haney, CR; Karczmar, GS; Markiewicz, E; Mustafi, D; Stadler, WM, 2013)
"HPS (hepatopulmonary syndrome) is characterized by oxygen desaturation in patients with chronic liver disease."	1.39	Sorafenib treatment improves hepatopulmonary syndrome in rats with biliary cirrhosis. ( Chang, CC; Chuang, CL; Hsieh, HG; Hsu, SJ; Huang, HC; Lee, FY; Lee, SD; Lin, HC; Teng, TH; Wang, SS, 2013)
"Sorafenib is a targeted drug approved for metastatic renal cell carcinoma but it has modest efficacy."	1.39	Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma. ( Benitez, A; Bowen, T; Lokeshwar, VB; Shamaldevi, N; Yates, TJ, 2013)
"Sorafenib signaling was characterized by quantitative PCR, Western blotting, immunofluorescence, and protein immunoprecipitation."	1.39	Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma. ( Campo, E; Colomer, D; López-Guerra, M; Montraveta, A; Navarro, A; Pérez-Galán, P; Rosich, L; Roué, G; Saborit-Villarroya, I; Xargay-Torrent, S, 2013)
"Parkinson's disease was induced by injection of MPTP in adult male C57BL/6 mice, nicotinamide (500 mg/kg,i."	1.38	[Protective effect of nicotinamide in a mouse Parkinson's disease model]. ( Jin, JH; Liang, J; Lu, Y; Luo, JH; Xu, J; Xu, SQ, 2012)
"Sorafenib was acutely administered to NASH rats with IR liver injury that were or were not chronically pretreated with the Rho-kinase-specific inhibitor fasudil."	1.38	Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis. ( Chan, CC; Huang, YT; Lee, KC; Lee, TY; Lin, HC; Yang, YY; Yeh, YC, 2012)
"Mcl-1, a survival factor in multiple myeloma, is downregulated at the protein level by sorafenib allowing for the execution of cell death, as ectopic overexpression of this protein protects multiple myeloma cells."	1.38	Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model. ( Björkholm, M; Celsing, F; De Raeve, H; Fristedt, C; Grandér, D; Gruber, A; Jernberg-Wiklund, H; Johnsson, P; Kharaziha, P; Kokaraki, G; Laane, E; Li, Q; Osterborg, A; Panaretakis, T; Panzar, M; Vanderkerken, K; Zhivotovsky, B, 2012)
"The sorafenib group had lower scores of total adhesions [1 (0-2."	1.38	The effect of sorafenib in postoperative adhesion formation in a rat uterine horn model. ( Altun, A; Boztosun, A; Gulturk, S; Kiliçkap, S; Müderris, II; Ozer, H; Yanik, A, 2012)
"Obesity is characterized by the accumulation of triacylglycerol in adipocytes."	1.37	A novel coenzyme A:diacylglycerol acyltransferase 1 inhibitor stimulates lipid metabolism in muscle and lowers weight in animal models of obesity. ( Aicher, TD; Kato, K; Kitamura, S; Miki, H; Nakada, Y; Pratt, SA; Yamaguchi, H; Yamamoto, T, 2011)
"Surgical resection is the first-line treatment for hepatocellular carcinoma (HCC) patients with well-preserved liver function."	1.37	Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. ( Cheng, SQ; Deng, YZ; Feng, YX; Guan, DX; Li, JJ; Li, N; Qin, Y; Wang, H; Wang, HY; Wang, T; Wang, XF; Wu, MC; Xie, D; Yang, P; Yao, F; Zhu, YQ, 2011)
"Treatment by sorafenib, at the contrary of gemcitabine alone or with oxaliplatine, resulted in a significant reduction in tumor volumes and prolongation of actuarial survival."	1.37	[Contribution of microCT structural imaging to preclinical evaluation of hepatocellular carcinoma chemotherapeutics on orthotopic graft in ACI rats]. ( Akladios, CY; Aprahamian, M; Balboni, G; Bour, G; Marescaux, J; Mutter, D, 2011)
"In vivo, NA significantly attenuated liver fibrosis in TAA-treated rats as assessed by histological analysis using hematoxylin-eosin and Masson's trichrome staining."	1.37	Nicotinamide inhibits hepatic fibrosis by suppressing DNA synthesis and enhancing apoptosis of hepatic stellate cells. ( Jang, JJ; Jin, J; Lee, KB; Park, SY, 2011)
"Sorafenib in combination with cytarabine resulted in strong anti-AML activity in vitro and in vivo."	1.37	Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. ( Baker, SD; Calabrese, C; Campana, D; Fan, Y; Hu, S; Inaba, H; Niu, H; Orwick, S; Panetta, JC; Pounds, S; Rehg, JE; Rose, C; Rubnitz, JE; Yang, S, 2011)
"Urinary bladder cancer is often a result of exposure to chemical carcinogens such as cigarette smoking."	1.37	Identification of gene expression signature modulated by nicotinamide in a mouse bladder cancer model. ( Bae, SC; Kim, J; Kim, SK; Kim, WJ; Lee, OJ; Yun, SJ, 2011)
"Memory loss is the signature feature of Alzheimer's disease, and therapies that prevent or delay its onset are urgently needed."	1.35	Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. ( Green, KN; LaFerla, FM; Martinez-Coria, H; Schreiber, SS; Steffan, JS; Sun, X; Thompson, LM, 2008)
"Sorafenib did not inhibit rhIL-2-induced natural killer cell expansion and rhIL-2 had no effect on the anti-angiogenic activity of sorafenib."	1.35	Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma. ( Abe, K; Arimura, A; Hojo, K; Iguchi, M; Matsumoto, M; Matsuo, Y; Wada, T, 2009)
"Sorafenib treatment also caused up-regulation of p-c-Raf Ser338 and p-extracellular signal-regulated kinase (ERK) Thr202/Tyr204 in gastric cancer xenografts."	1.35	AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer. ( Chong, LW; Chow, P; Chung, A; Huynh, H; Koong, HN; Lam, WL; Lee, J; Lee, SS; Lew, GB; Ngo, VC; Ong, HS; Ong, WJ; Soo, KC; Thng, CH; Yang, S, 2009)
"Sorafenib treatment (daily gavage, 2."	1.35	Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. ( Desai, AA; Garcia, JG; Gomberg-Maitland, M; Husain, AN; Lang, RM; Liu, Y; Lussier, YA; Maitland, ML; Moreno-Vinasco, L; Ratain, MJ; Sam, L; Sammani, S; Singleton, PA, 2008)
"After induction of type 2 diabetes, rats received daily injections of AG (50 mg kg(-1), i."	1.35	Aminoguanidine prevents the impairment of cardiac pumping mechanics in rats with streptozotocin and nicotinamide-induced type 2 diabetes. ( Chang, KC; Liang, JT; Lin, YD; Tseng, YZ; Wu, ET; Wu, MS, 2008)
"Perinatal asphyxia was induced by immersing foetuses-containing uterine horns removed from ready-to-deliver rats into a water bath for 16 or 20 min."	1.34	Nicotinamide prevents the effect of perinatal asphyxia on dopamine release evaluated with in vivo microdialysis 3 months after birth. ( Bustamante, D; Goiny, M; Herrera-Marschitz, M; Morales, P; Pereyra, JT, 2007)
"Perinatal asphyxia was induced in vivo by immersing foetuses-containing uterine horns removed from ready-to-deliver rats into a water bath for 20 min."	1.34	Plasticity of basal ganglia neurocircuitries following perinatal asphyxia: effect of nicotinamide. ( Bustamante, D; Gomez-Urquijo, S; Herrera-Marschitz, M; Hökfelt, T; Klawitter, V; Morales, P, 2007)
"However, in chronic renal failure (CRF), serum 1,25(OH)(2)D and Pi levels are often abnormal."	1.33	Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. ( Eto, N; Miyata, Y; Ohno, H; Yamashita, T, 2005)
"NCX is an attractive target for the treatment of heart failure and ischemia-reperfusion."	1.33	Discovery of an N-(2-aminopyridin-4-ylmethyl)nicotinamide derivative: a potent and orally bioavailable NCX inhibitor. ( Kakefuda, A; Kuramochi, T; Sakamoto, S; Taguchi, T; Tsukamoto, I; Yamada, H, 2005)
" After approximately one month in vitro (DIV 25), the cultures were treated for immunocytochemistry to characterise neuronal phenotype with markers against the N-methyl-D-aspartate receptor subunit 1 (NR1), the dopamine pacemaker enzyme tyrosine hydroxylase (TH), and nitric oxide synthase (NOS), the enzyme regulating the bioavailability of NO."	1.33	Plasticity of the central nervous system (CNS) following perinatal asphyxia: does nicotinamide provide neuroprotection? ( Bustamante, D; Goiny, M; Herrera-Marschitz, M; Klawitter, V; Morales, P, 2006)
"Oral administration of ML120B inhibited paw swelling in a dose-dependent manner (median effective dosage 12 mg/kg twice daily) and offered significant protection against arthritis-induced weight loss as well as cartilage and bone erosion."	1.33	IKKbeta inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis. ( Anderson, K; Chandra, S; DuPont, M; Gangurde, P; Harriman, G; Hepperle, M; Jaffee, B; Kujawa, J; Lane, J; Morgan, J; Ocain, T; Savinainen, A; Schopf, L; Siebert, E; Silva, M; Wen, D; Xu, Y, 2006)
" The dosage of 230 mg/kg of nicotinamide given intraperitoneally 15 min before STZ administration (65 mg/kg i."	1.32	Alterations in vascular endothelial function in the aorta and mesenteric artery in type II diabetic rats. ( Kamata, K; Kobayashi, T; Matsumoto, T; Wakabayashi, K, 2004)
"Most human neurodegenerative diseases have a number of common features, including adult onset, progressive degeneration of selected neuronal populations and formation of abnormal protein aggregates."	1.32	Comparison of pathways controlling toxicity in the eye and brain in Drosophila models of human neurodegenerative diseases. ( Feany, MB; Ghosh, S, 2004)
"Pimonidazole was used as a marker of hypoxia and was analyzed with a digital image processing system."	1.31	Effects of nicotinamide and carbogen on oxygenation in human tumor xenografts measured with luminescense based fiber-optic probes. ( Bussink, J; Kaanders, JH; Strik, AM; van der Kogel, AJ, 2000)
"Late treatment with nicorandil had no effect on infarct size (43."	1.30	Myocardial protection afforded by nicorandil and ischaemic preconditioning in a rabbit infarct model in vivo. ( Baxter, GF; Imagawa, J; Yellon, DM, 1998)
" Among the various dosages of nicotinamide tested in 3-month-old Wistar rats (100-350 mg/kg body wt), the dosage of 230 mg/kg, given intraperitoneally 15 min before STZ administration (65 mg/kg i."	1.30	Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide. ( Broca, C; Gross, R; Hillaire-Buys, D; Manteghetti, M; Masiello, P; Novelli, M; Ribes, G; Roye, M, 1998)
"We used the human hypopharyngeal squamous cell carcinoma cell line FaDu implanted in immune-deficient SCID mice and assessed its response to radiation by cell survival and by growth delay."	1.30	Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation. ( Brown, JM; Dorie, MJ; el-Said, A; Menke, D, 1999)
"Fetal hydrocephalus was induced by single intraperitoneal injection of 8 mg/kg 6-aminonicotinamide (6-AN), a niacinamide antagonist, in Sprague-Dawley rat on day 13 of gestation."	1.28	Congenital hydrocephalus mimicking Dandy-Walker syndrome induced by 6-aminonicotinamide injection in pregnant rat. ( Matsumoto, S; Oi, S; Tamaki, N; Taomoto, K; Yamada, H, 1991)
"Hydrocephalus with aqueduct stenosis was a consistent feature in mice which received a single intraperitoneal injection of 6-aminonicotinamide (6-AN) on day 5 postnatal."	1.27	Aqueduct stenosis induced by a single injection of antivitamin. ( Aikawa, H; Suzuki, K, 1985)
"During the early stages of hydrocephalus (7-9 days after injection), aqueductal lesions were characterized by edematous ependymal and subependymal cells, and spongy changes in the periaqueductal area, which resulted in aqueduct stenosis."	1.27	Aqueductal lesions in 6-aminonicotinamide-treated suckling mice. ( Aikawa, H; Kobayashi, S; Suzuki, K, 1986)

Research

Studies (417)

Authors

Clinical Trials (24)

Trial Overview

Trial Outcomes

Safety and Tolerability of RJX as Assessed by Electrocardiograms (ECGs).

Timeframe	Studies, this research(%)	All Research%
pre-1990	21 (5.04)	18.7374
1990's	23 (5.52)	18.2507
2000's	67 (16.07)	29.6817
2010's	257 (61.63)	24.3611
2020's	49 (11.75)	2.80

Authors	Studies
César, IC	1
Godin, AM	2
Araujo, DP	1
Oliveira, FC	1
Menezes, RR	1
Santos, JR	1
Almeida, MO	1
Dutra, MM	1
Santos, DA	1
Machado, RR	1
Pianetti, GA	1
Coelho, MM	2
de Fátima, A	1
Sun, Y	4
Zhang, Y	10
Li, Y	3
Cheng, J	2
Chen, S	1
Xiao, Y	1
Ao, G	1
Farooqi, AS	1
Hong, JY	1
Cao, J	3
Lu, X	2
Price, IR	1
Zhao, Q	1
Kosciuk, T	1
Yang, M	1
Bai, JJ	1
Lin, H	3
Abrams, RPM	1
Yasgar, A	1
Teramoto, T	1
Lee, MH	1
Dorjsuren, D	1
Eastman, RT	1
Malik, N	1
Zakharov, AV	1
Li, W	2
Bachani, M	1
Brimacombe, K	1
Steiner, JP	1
Hall, MD	1
Balasubramanian, A	1
Jadhav, A	1
Padmanabhan, R	1
Simeonov, A	1
Nath, A	1
Cyr, A	1
Kohut, L	1
Chambers, L	1
Stratimirovic, S	1
Zuckerbraun, B	1
Zhang, Q	5
Li, J	5
Zhong, H	2
Xu, Y	4
Mierzejewska, P	1
Kunc, M	1
Zabielska-Kaczorowska, MA	1
Kutryb-Zajac, B	2
Pelikant-Malecka, I	1
Braczko, A	1
Jablonska, P	1
Romaszko, P	1
Koszalka, P	1
Szade, J	1
Smolenski, RT	2
Slominska, EM	2
Podyacheva, E	1
Toropova, Y	1
Sugahara, S	1
Hanaoka, K	1
Emori, T	1
Takeshita, N	1
Fujii, Y	1
Nakano, M	1
Suzuki, T	2
Takahashi, J	1
Nakamura, Y	1
Hamity, MV	2
Kolker, SJ	1
Hegarty, DM	1
Blum, C	1
Langmack, L	1
Aicher, SA	1
Hammond, DL	2
Zhang, X	3
Tian, B	1
Deng, Q	1
Ding, X	1
Liu, Q	2
Ye, C	1
Deng, C	1
Qiu, L	1
Guo, C	1
Liu, X	2
Zhou, Q	1
Huang, Y	2
Fan, Z	2
Duan, H	1
Wang, M	2
Li, Z	4
Xie, L	1
Cercillieux, A	2
Ciarlo, E	1
Canto, C	3
Uckun, FM	1
Saeed, M	1
Awili, M	1
Ozercan, IH	2
Qazi, S	1
Lee, C	2
Shibli, A	1
Skolnick, AW	1
Prusmack, A	1
Varon, J	1
Barrera, CI	1
Orhan, C	2
Volk, M	1
Sahin, K	2
Lazarini-Lopes, W	1
Campos-Rodriguez, C	1
Garcia-Cairasco, N	1
N'Gouemo, P	1
Forcelli, PA	1
Cieminski, K	1
Flis, DJ	1
Dzik, KP	1
Kaczor, JJ	1
Wieckowski, MR	1
Antosiewicz, J	1
Ziolkowski, W	1
Zhu, X	1
Wang, H	4
Gasior, FM	1
Lin, S	1
Justice, CN	1
O'Donnell, JM	1
Vanden Hoek, TL	1
Bazhanova, ED	1
Sokolova, YO	1
Teplyi, DL	1
Tani, T	1
Fujiwara, M	1
Orimo, H	1
Shimizu, A	1
Narisawa, S	1
Pinkerton, AB	2
Millán, JL	2
Tsuruoka, S	1
Pooranachithra, M	1
Bhaskar, JP	1
Murali, D	1
Das, SS	1
JebaMercy, G	1
Krishnan, V	1
Balamurugan, K	1
Kong, ZL	1
Sudirman, S	1
Hsu, YC	1
Su, CY	1
Kuo, HP	1
Sambeat, A	1
Ratajczak, J	1
Joffraud, M	1
Sanchez-Garcia, JL	1
Giner, MP	1
Valsesia, A	1
Giroud-Gerbetant, J	1
Valera-Alberni, M	1
Boutant, M	1
Kulkarni, SS	1
Moco, S	1
Eide, CA	1
Zabriskie, MS	1
Savage Stevens, SL	1
Antelope, O	1
Vellore, NA	1
Than, H	1
Schultz, AR	1
Clair, P	1
Bowler, AD	1
Pomicter, AD	1
Yan, D	1
Senina, AV	1
Qiang, W	1
Kelley, TW	1
Szankasi, P	1
Heinrich, MC	1
Tyner, JW	1
Rea, D	1
Cayuela, JM	1
Kim, DW	1
Tognon, CE	1
O'Hare, T	1
Druker, BJ	1
Deininger, MW	1
Meng, Z	2
Liu, F	1
Zhou, L	2
Su, M	1
Meng, Y	1
Zhang, S	2
Liao, X	1
Cao, Z	1
Lu, H	2
Ren, MT	1
Gu, ML	1
Zhou, XX	1
Yu, MS	1
Pan, HH	1
Ji, F	1
Ding, CY	1
Horimatsu, T	1
Blomkalns, AL	1
Ogbi, M	1
Moses, M	1
Kim, D	2
Patel, S	1
Gilreath, N	1
Reid, L	1
Benson, TW	1
Pye, J	1
Ahmadieh, S	1
Thompson, A	1
Robbins, N	1
Mann, A	1
Edgell, A	1
Benjamin, S	1
Stansfield, BK	1
Huo, Y	1
Fulton, DJ	1
Agarwal, G	1
Singh, N	1
Offermanns, S	1
Weintraub, NL	1
Kim, HW	1
Panda, BP	1
Krishnamoorthy, R	1
Bhattamisra, SK	1
Shivashekaregowda, NKH	1
Seng, LB	1
Patnaik, S	1
Jiang, Y	1
Liu, Y	5
Gao, M	1
Xue, M	1
Wang, Z	3
Liang, H	1
Kim, H	1
Kim, B	2
Kim, HS	1
Cho, JY	1
Luo, P	1
Yan, H	1
Chen, X	4
Zhao, Z	2
Zhu, Y	2
Du, J	1
Xu, Z	1
Zeng, S	1
Yang, B	2
Ma, S	1
He, Q	1
Joshi, U	1
Evans, JE	1
Pearson, A	1
Saltiel, N	1
Cseresznye, A	1
Darcey, T	1
Ojo, J	1
Keegan, AP	1
Oberlin, S	1
Mouzon, B	1
Paris, D	1
Klimas, N	1
Sullivan, K	1
Mullan, M	1
Crawford, F	1
Abdullah, L	1
Gerasimenko, M	1
Cherepanov, SM	1
Furuhara, K	1
Lopatina, O	1
Salmina, AB	1
Shabalova, AA	1
Tsuji, C	1
Yokoyama, S	1
Ishihara, K	1
Brenner, C	5
Higashida, H	1
Henneman, NF	1
Girardot, PE	1
Sellers, JT	1
Chrenek, MA	1
Wang, J	3
Nickerson, JM	1
Boatright, JH	1
Braidy, N	1
Park, KH	2
Kim, SH	2
Faivre, A	1
Katsyuba, E	1
Verissimo, T	1
Lindenmeyer, M	1
Rajaram, RD	1
Naesens, M	1
Heckenmeyer, C	1
Mottis, A	1
Feraille, E	1
Cippà, P	1
Cohen, C	1
Longchamp, A	1
Allagnat, F	1
Rutkowski, JM	1
Legouis, D	1
Auwerx, J	5
de Seigneux, S	1
Hu, Q	1
Xi, Y	2
Xing, Z	1
Zhang, Z	1
Huang, L	1
Wu, J	3
Liang, K	1
Nguyen, TK	1
Egranov, SD	1
Sun, C	1
Hawke, DH	1
Sun, D	1
Kim, JJ	1
Zhang, P	1
Farida, A	1
Hung, MC	1
Han, L	1
Darabi, R	1
Lin, C	1
Yang, L	1
Selvanesan, BC	1
Meena, K	1
Beck, A	1
Meheus, L	1
Lara, O	1
Rooman, I	1
Gravekamp, C	1
Zhao, J	1
Tang, WQ	1
Ji, CH	1
Gu, JH	1
Jiang, B	2
Yeom, DH	1
Lee, YS	1
Ryu, I	1
Lee, S	1
Sung, B	1
Lee, HB	1
Ahn, JH	1
Ha, E	1
Choi, YS	1
Lee, SH	2
You, WK	1
Yokouchi, C	2
Nishimura, Y	1
Goto, H	2
Sato, M	1
Hidoh, Y	1
Takeuchi, K	2
Ishii, Y	2
Kumakura, S	1
Sato, E	4
Sekimoto, A	4
Hashizume, Y	1
Yamakage, S	1
Miyazaki, M	1
Ito, S	5
Harigae, H	1
Takahashi, N	5
Mattiello, L	1
Pucci, G	1
Marchetti, F	1
Diederich, M	1
Gonfloni, S	1
Verma, H	1
Garg, R	1
Jia, Z	1
Dai, J	1
Kong, J	1
Li, G	3
Wu, W	3
Fu, Y	1
Liu, Z	4
Shu, S	2
Wang, Y	5
Tang, C	2
Cai, J	2
Dong, Z	2
Dan, X	1
Hou, Y	1
Lee, JH	4
Wechter, N	1
Krishnamurthy, S	1
Kimura, R	1
Babbar, M	1
Demarest, T	1
McDevitt, R	1
Mattson, MP	2
Croteau, DL	1
Bohr, VA	2
Kang, K	1
Pan, D	1
Chang, B	1
Sang, LX	1
Tannous, C	2
Deloux, R	2
Karoui, A	1
Mougenot, N	3
Burkin, D	1
Blanc, J	2
Coletti, D	1
Lavery, G	1
Mericskay, M	3
Tong, D	1
Schiattarella, GG	1
Jiang, N	1
Altamirano, F	1
Szweda, PA	1
Elnwasany, A	1
Lee, DI	1
Yoo, H	1
Kass, DA	1
Szweda, LI	1
Lavandero, S	1
Verdin, E	1
Gillette, TG	1
Hill, JA	1
Hosseini, L	1
Mahmoudi, J	1
Pashazadeh, F	1
Salehi-Pourmehr, H	1
Sadigh-Eteghad, S	1
Tribble, JR	1
Otmani, A	1
Sun, S	1
Ellis, SA	1
Cimaglia, G	1
Vohra, R	1
Jöe, M	1
Lardner, E	1
Venkataraman, AP	1
Domínguez-Vicent, A	1
Kokkali, E	1
Rho, S	1
Jóhannesson, G	1
Burgess, RW	1
Fuerst, PG	1
Brautaset, R	1
Kolko, M	1
Morgan, JE	1
Crowston, JG	1
Votruba, M	1
Williams, PA	1
Yu, Y	1
Fedele, G	1
Celardo, I	2
Loh, SHY	1
Martins, LM	2
Dufu, K	2
Williams, AT	1
Muller, CR	1
Walser, CM	1
Lucas, A	1
Eaker, AM	1
Alt, C	1
Cathers, BE	1
Oksenberg, D	1
Cabrales, P	1
Kucuk, O	1
Tuzcu, M	1
Durmus, AS	1
Sahin, N	1
Juturu, V	1
Lopez-Sanz, L	1
Bernal, S	1
Jimenez-Castilla, L	1
Prieto, I	1
La Manna, S	1
Gomez-Lopez, S	1
Blanco-Colio, LM	1
Egido, J	1
Martin-Ventura, JL	1
Gomez-Guerrero, C	1
Wright, MB	1
Varona Santos, J	1
Kemmer, C	1
Maugeais, C	1
Carralot, JP	1
Roever, S	1
Molina, J	1
Ducasa, GM	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 1, Double-blind, Placebo-controlled, Randomized, Two-Part, Ascending Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Rejuveinix (RJX) in Healthy Participants[NCT03680105]	Phase 1	76 participants (Actual)	Interventional	2018-08-24	Completed
Nicotinamide Riboside in Ulcerative Colitis[NCT05561738]		40 participants (Anticipated)	Interventional	2024-01-01	Not yet recruiting
Center-Based and Home-Based Walking Exercise Intervention to Reduce Fatigue in Older Breast Cancer Survivors[NCT05684367]		24 participants (Anticipated)	Interventional	2023-11-29	Recruiting
A Randomized Double-blind Placebo-controlled Clinical Trial of Nicotinamide Riboside for Restoring Mitochondrial Bioenergetics in Gulf War Illness[NCT05243290]		52 participants (Anticipated)	Interventional	2022-04-13	Recruiting
An Open-label, Dose-escalation and Expansion Phase 1/2a Clinical Trial to Assess the Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and the Anti-tumor Efficacy of NOV1501 (ABL001) in Patients With Advanced Solid Tumors[NCT03292783]	Phase 1	45 participants (Actual)	Interventional	2017-09-18	Completed
Nicotinamide Riboside (NR) in Paclitaxel-induced Peripheral Neuropathy[NCT03642990]	Phase 2	5 participants (Actual)	Interventional	2019-11-08	Terminated (stopped due to Enrollment challenges)
Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study[NCT05695027]	Phase 2/Phase 3	188 participants (Anticipated)	Interventional	2023-03-14	Recruiting
Nutritional Supplements and Performance During Visual Field Testing[NCT03797469]		32 participants (Actual)	Interventional	2019-04-15	Completed
Validation of an Enzymatic Assay for Quantification of Nicotinamide Adenine Dinucleotide in Blood Plasma After Ingestion of the Vitamin B3 Variant Nicotinamide Riboside: a Randomized Controlled Trial[NCT06005350]		54 participants (Anticipated)	Interventional	2023-11-01	Recruiting
Impact of the Combined Treatment of Curcumin and Resveratrol Liposomed Polyphenols With G04CB02 on the Clinical Improvement of ALS Patients[NCT04654689]	Phase 2	90 participants (Actual)	Interventional	2021-11-20	Completed
A Prospective Randomized Control Trial of the Effect of Sorafenib Combined With Aspirin in Preventing the Recurrence in High-risk Patients With Hepatocellular Carcinoma[NCT02748304]		52 participants (Actual)	Interventional	2016-04-30	Terminated (stopped due to The enrollment of this study was slow. With the approval of lenvatinib in HCC,many patients choose the new drug, so subsequent enrollment may be more difficult.)
Phase I Study of Vorinostat in Combination With Niacinamide, and Etoposide for the Treatment of Patients With Relapsed and Refractory Lymphoid Malignancies[NCT00691210]	Phase 1	40 participants (Actual)	Interventional	2008-06-30	Completed
The Effect of Niacin Supplementation on Systemic Nicotinamide Adenine Dinucleotide (NAD+) Metabolism, Physiology and Muscle Performance in Healthy Controls and Mitochondrial Myopathy Patients[NCT03973203]		15 participants (Actual)	Interventional	2014-06-01	Completed
NiaMIT (NiaMIT_0001) Continuation for Early-stage Mitochondrial Myopathy Patients to Investigate the Effect of Niacin Supplementation on Systemic Nicotinamide Adenine Dinucleotide (NAD+) Metabolism, Physiology and Muscle Performance[NCT04538521]		3 participants (Actual)	Interventional	2019-02-11	Completed
Stereotactic Body Radiation Therapy Plus Pembrolizumab and Trametinib vs. Stereotactic Body Radiation Therapy Plus Gemcitabine for Locally Recurrent Pancreatic Cancer After Surgical Resection: an Open-label, Randomized, Controlled, Phase 2 Trial[NCT02704156]	Phase 2	170 participants (Actual)	Interventional	2016-10-31	Completed
A Double-Blind-Randomized, Placebo-Controlled Adaptive Design Trial of Nicotinamide in Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease Dementia[NCT03061474]	Phase 2	46 participants (Actual)	Interventional	2017-07-12	Completed
A Phase 1/2 Study of AZD6244 in Combination With Sorafenib in Advanced Hepatocellular Carcinoma[NCT01029418]	Phase 1/Phase 2	30 participants (Actual)	Interventional	2009-11-30	Terminated (stopped due to The phase II portion was not conducted due to funding issue.)
A Phase II Study of Binimetinib in Children and Adults With NF1 Associated Plexiform Neurofibromas (PNOC010)[NCT03231306]	Phase 2	40 participants (Anticipated)	Interventional	2017-11-28	Active, not recruiting
Developing Novel Biomarkers of Plexiform Neurofibroma Tumor Burden[NCT05238909]		200 participants (Anticipated)	Observational [Patient Registry]	2022-03-04	Recruiting
Randomized Double-blinded Comparative Trial to Study the Add-on Activity of Combination Treatment of Nicotinamide on Progression Free Survival for EGFR Mutated Lung Cancer Terminal Stage Patients Being Treated With Gefitinib or Erlotinib[NCT02416739]	Phase 2/Phase 3	110 participants (Actual)	Interventional	2015-03-31	Active, not recruiting
Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer[NCT02363647]		10 participants (Actual)	Interventional	2015-01-31	Terminated (stopped due to No Current Funding)
TrialNet Pathway to Prevention of T1D[NCT00097292]		75,000 participants (Anticipated)	Observational	2004-02-29	Recruiting
Comparison of Nicotinamide and Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients[NCT01011699]	Phase 3	176 participants (Actual)	Interventional	2010-01-31	Terminated (stopped due to Financial problem)
Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance[NCT01723839]	Phase 2	21 participants (Actual)	Interventional	2012-02-22	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Number of participants with abnormal and clinically significant findings based on ECG. (NCT03680105)
Timeframe: Up to Day 2 for Part 1 and Up to Day 8 for Part 2

Safety and Tolerability of RJX as Assessed by Neurological Examinations.

Intervention	Participants (Count of Participants)
Part 1; Placebo	0
Part 1; Cohort 1; RJX	0
Part 1; Cohort 2; RJX	0
Part 1; Cohort 3; RJX	0
Part 1; Cohort 4; RJX	0
Part 1; Cohort 5; RJX	0
Part 1; Cohort 6; RJX	0
Part 2; Placebo	0
Part 2; Cohort 1; RJX	0
Part 2; Cohort 2; RJX	0
Part 2; Cohort 3; RJX	0

Number of participants with clinically significant values and actual changes from baseline of continuous neurological assessments. (NCT03680105)
Timeframe: Up to Day 5 for Part 1 and Up to Day 12 for Part 2

Treatment-related Adverse Events (TEAE) Reporting of RJX

Intervention	Participants (Count of Participants)
Part 1; Placebo	0
Part 1; Cohort 1; RJX	0
Part 1; Cohort 2; RJX	0
Part 1; Cohort 3; RJX	0
Part 1; Cohort 4; RJX	0
Part 1; Cohort 5; RJX	0
Part 1; Cohort 6; RJX	0
Part 2; Placebo	0
Part 2; Cohort 1; RJX	0
Part 2; Cohort 2; RJX	1
Part 2; Cohort 3; RJX	0

Number of participants with indicated AEs receiving RJX as assessed by CTCAE v4 03 (NCT03680105)
Timeframe: Up to Day 5 for Part 1 and Up to Day 12 for Part 2

Difference in Score Between Baseline and End of Treatment for the FACT&GOG-NTX Subscale .

Intervention	Participants (Count of Participants)
	Mild TEAE72191553	Mild TEAE72191554	Mild TEAE72191555	Mild TEAE72191556	Mild TEAE72191557	Mild TEAE72191558	Mild TEAE72191559	Mild TEAE72191560	Mild TEAE72191562	Mild TEAE72191563	Mild TEAE72191561	Moderate TEAE72191553	Moderate TEAE72191554	Moderate TEAE72191555	Moderate TEAE72191556	Moderate TEAE72191557	Moderate TEAE72191558	Moderate TEAE72191559	Moderate TEAE72191560	Moderate TEAE72191561	Moderate TEAE72191562	Moderate TEAE72191563	Severe TEAE72191553	Severe TEAE72191554	Severe TEAE72191555	Severe TEAE72191556	Severe TEAE72191557	Severe TEAE72191558	Severe TEAE72191559	Severe TEAE72191560	Severe TEAE72191561	Severe TEAE72191562	Severe TEAE72191563	Related TEAE72191553	Related TEAE72191554	Related TEAE72191555	Related TEAE72191556	Related TEAE72191558	Related TEAE72191559	Related TEAE72191560	Related TEAE72191561	Related TEAE72191562	Related TEAE72191563	Related TEAE72191557
	Without TEAE	With TEAE
Part 1; Placebo	2
Part 1; Cohort 1; RJX	1
Part 1; Cohort 2; RJX	2
Part 1; Cohort 3; RJX	0
Part 1; Cohort 4; RJX	2
Part 1; Cohort 5; RJX	2
Part 1; Cohort 6; RJX	0
Part 2; Placebo	1
Part 2; Cohort 1; RJX	1
Part 2; Cohort 2; RJX	3
Part 2; Cohort 3; RJX	2
Part 1; Placebo	11
Part 1; Cohort 1; RJX	5
Part 1; Cohort 2; RJX	4
Part 1; Cohort 3; RJX	6
Part 1; Cohort 5; RJX	4
Part 1; Cohort 6; RJX	9
Part 2; Placebo	5
Part 2; Cohort 1; RJX	5
Part 2; Cohort 3; RJX	4
Part 1; Placebo	0
Part 1; Cohort 1; RJX	0
Part 1; Cohort 4; RJX	1
Part 1; Cohort 5; RJX	1
Part 2; Cohort 1; RJX	0
Part 2; Cohort 2; RJX	0
Part 2; Cohort 3; RJX	1
Part 1; Placebo	13
Part 1; Cohort 1; RJX	6
Part 1; Cohort 2; RJX	6
Part 1; Cohort 4; RJX	5
Part 1; Cohort 5; RJX	5
Part 2; Cohort 1; RJX	6
Part 2; Cohort 2; RJX	6
Part 2; Cohort 3; RJX	5
Part 1; Cohort 2; RJX	0
Part 1; Cohort 4; RJX	0
Part 1; Cohort 5; RJX	0
Part 2; Placebo	0
Part 1; Cohort 4; RJX	6
Part 1; Cohort 5; RJX	6
Part 2; Placebo	6
Part 1; Cohort 2; RJX	1
Part 2; Cohort 2; RJX	2
Part 2; Cohort 3; RJX	0
Part 1; Cohort 2; RJX	5
Part 1; Cohort 4; RJX	4
Part 2; Cohort 2; RJX	4
Part 2; Cohort 3; RJX	6

Difference in Score on the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity questionnaire at the end of treatment; i.e. Score at screening - score at end of treatment. This questionnaire asks 11 questions that are specific to chemotherapy-induced peripheral neuropathies. Maximum score is 44, minimum score is 0. Positive differences indicate a decrease in neuropathy. Negative differences indicate a worsening of neuropathy. Zero means unchanged. (NCT03642990)
Timeframe: 4 weeks

Difference in Total Neuropathy Score Between Screening and End of Treatment

Intervention	units on a scale (Median)
NIAGEN®)	7

Exploratory analysis of ability of the clinical version of the Total Neuropathy Score questionnaire to detect changes in CIPN severity over time. Unlike the CTCAE or the FACT&GOG-NTX questionnaires, the TNS is a patient reported outcome measure. HIghest score (worse neuropathy is 24, lowest score is 0. Outcome assessed difference between end of treatment and screening. A positive number indicates improvement in neuropathy (NCT03642990)
Timeframe: 4 weeks

Number of Dose Reduction Events

Intervention	score on a scale (Median)
NIAGEN®)	2

Count the number of (i.e. the incidence) of dose reduction events due to neuropathy (each occasion of dose reduction is a separate event); (NCT03642990)
Timeframe: 3 weeks

Number of Participants With No Worsening in the Grade of Peripheral Sensory Neuropathy as Scored by CTCAE

Intervention	event (Number)
NIAGEN®)	0

"The primary outcome variable is defined as no worsening of the grade of peripheral sensory neuropathy as scored according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 guidelines. Per the CTCAE a score of 1 would be assigned in the instance of parethesias or a loss of deep tendon reflexes. A score of 2 would be assigned in the instance of moderate symptoms that limit instrumental activities of daily living. A score of 3 would be assigned in the instance of severe symptoms that limit self-care activities of daily living. Because the outcome measure is defined as no worsening of the grade, it was recorded as either yes( i.e. it worsened) or no (i.e. it did not worsen)." (NCT03642990)
Timeframe: approximately 4 weeks

Percentage of Patients in Which Dose of Paclitaxel or Nab-Paclitaxel is Reduced Due to CIPN

Intervention	Participants (Count of Participants)
NIAGEN®)	3

Quantitate the percentage of patients that experience a dose reduction of paclitaxel or nab-paclitaxel therapy due to neuropathy. (NCT03642990)
Timeframe: 3 weeks

Plasma Concentration of Paclitaxel After NIAGEN Treatment Began

Intervention	Participants (Count of Participants)
NIAGEN®)	0

Paclitaxel levels in plasma were measured ~30 min after each infusion of taxane. This was undertaken to ascertain whether NIAGEN altered plasma levels of paclitaxel because increases or decreases in plasma levels of paclitaxel by itself could lead to an apparent worsening or improvement, respectively, in CIPN and confound interpretation of NIAGEN's effect. (NCT03642990)
Timeframe: up to 3 weeks

Total Dose of Paclitaxel Administered

Intervention	ng/ml (Median)
NIAGEN®)	810

Quantitate the total cumulative dose of paclitaxel administered over the 12 weeks. (NCT03642990)
Timeframe: 3 weeks

The Greatest Number of Cycles Received in Each Treatment Group

Intervention	mg/M^2 (Number)
NIAGEN®)	200

The highest number of cycles received by an individual participant in the treatment groups. Each cycle was 21 days long. (NCT00691210)
Timeframe: up to 45 weeks

The Maximum Tolerated Dose (MTD) of Niacinamide in the Combination of Vorinostat and Niacinamide

The Median Progression Free Survival Time Will be Determined.

Intervention	cycles (Number)
Vorinostat (SAHA) and Niacinamide: Level 1	9
Vorinostat (SAHA) and Niacinamide: Level 2	12
Vorinostat (SAHA) and Niacinamide: Level 3	15
Vorinostat (SAHA) and Niacinamide: Level 4	10
Vorinostat (SAHA) and Niacinamide: Level 5	14
Vorinostat, Niacinamide and Etoposide: Level 1	3
Vorinostat, Niacinamide and Etoposide: Level 2	4

Intervention	mg/kg (Number)
Vorinostat (SAHA) and Niacinamide: Level 1-5	100

The time from the start of treatment until documentation of any clinical or radiological disease progression or death, whichever occurred first. Progression is assessed by the Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT02704156)
Timeframe: 3 years

The Median Survival Time Will be Determined.

One- and Two-year Overall Survival Rate Will be Determined.

Intervention	months (Median)
SBRT Plus Gemcitabine	5.4
SBRT Plus Pembrolizumab and Trametinib	8.2

Intervention	months (Median)
SBRT Plus Gemcitabine	12.8
SBRT Plus Pembrolizumab and Trametinib	14.9

The number of patients alive at 1 year and 2 years. (NCT02704156)
Timeframe: 2 year

One- and Two-year Progression Survival Rate Will be Determined. Will be Determined.

Intervention	Participants (Count of Participants)
	1-year OS rate	2-year OS rate
SBRT Plus Gemcitabine	48	0
SBRT Plus Pembrolizumab and Trametinib	53	2

The proportion of patients without disease progressions at 1 year and 2 years. (NCT02704156)
Timeframe: 2 years

The Quality of Life Will be Analyzed.

Intervention	Participants (Count of Participants)
	1-year PFS rate	2-year PFS rate
SBRT Plus Gemcitabine	7	0
SBRT Plus Pembrolizumab and Trametinib	18	0

The analysis of quality of life is based on European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30). All scales and subscales range from 0 to 100. Regarding physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning and global health, higher scores may indicate better outcomes. In the case of fatigue, nausea and vomitting, pain, dyspnea, insomina, appetite loss, constipation, diarrhea and financial difficulties, lower scores may indicate better outcomes. Scales of all items are independent and not combined to compute a total score. (NCT02704156)
Timeframe: 3 years

Treatment-related Adverse Effects Will be Determined.

Intervention	units on a scale (Mean)
	Physical functioning	Role functioning	Emotional functioning	Cognitive functioning	Social functioning	Global health	Fatigue	Nausea and vomitting	Pain	Dyspnea	Insomina	Appetite loss	Constipation	Diarrhea	Financial difficulties
SBRT Plus Gemcitabine	86.2	81.8	73.9	84.7	85.5	83.6	29.6	29.4	23.9	16.1	14.9	31.0	14.5	15.7	16.8
SBRT Plus Pembrolizumab and Trametinib	83.7	84.5	72.1	83.3	84.1	83.2	26.6	28.8	26.5	13.7	17.6	33.3	16.5	15.7	17.2

Treatment-related adverse effects are determined by National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0. (NCT02704156)
Timeframe: 3 years

Activities of Daily Living - Mild Cognitive Impairment

Intervention	Participants (Count of Participants)
	Grade 3 pyrexia	Grade 3 vomitting	Grade 3 and 4 increased ALT or AST	Grade 3 stomatitis	Grade 3 rash	Grade 3 and 4 neutropenia	Grade 3 thrombocytopenia	Grade 3 increased blood bilirubin	Grade 3 hypokalemia	Grade 3 hyponatremia	Grade 3 pneumonia	Grade 3 hypertension
SBRT Plus Gemcitabine	0	2	6	0	0	9	4	0	0	0	0	0
SBRT Plus Pembrolizumab and Trametinib	2	1	10	1	2	1	1	4	1	3	1	2

The ADCS-ADL-MCI is a measure of patient functional performance in Alzheimer's Disease and Mild Cognitive Impairment trials. The informant-based questionnaire assesses conduct of basic and instrumental Activities of Daily Living (ADLs). A total of 24 ADLs are evaluated. Scores range from 0 to 53, with higher scores representing more maintained function. (NCT03061474)
Timeframe: Baseline to 48 weeks

ADASCog-13

Intervention	score on a scale (Mean)
Nicotinamide	-4.05
Placebo	-1.39

ADAS-Cog13 is a structured scale that evaluates memory (immediate and delayed word recall; immediate word recognition), receptive and expressive language, orientation, ideational praxis (preparing a letter for mailing), constructional praxis (copying figures), and attention (number cancellation). Ratings of spoken language, language comprehension, word finding difficulty, and ability to remember test instructions also are obtained. Range: 0-85; higher scores indicate greater impairment. (NCT03061474)
Timeframe: Baseline to 48 weeks

CDR Sum of Boxes

Intervention	score on a scale (Mean)
Nicotinamide	3.2
Placebo	5.16

CDR-SB is a composite rating of cognition and everyday function which incorporates both informant input and direct assessment of performance. It assesses through semi-structured interview three cognitive domains (memory, orientation, and judgement/problem solving) and three everyday functional domains (community affairs, home and hobbies, personal care). Level of impairment in each of the six domains is rated from none (score=0) to severe (score=3). The six domain scores are then summed to create the CDR-SB. Range 0-18; higher scores indicate greater impairment. (NCT03061474)
Timeframe: Baseline to 48 weeks

Change in ab40

Intervention	score on a scale (Mean)
Nicotinamide	0.76
Placebo	2.18

Change in key peptide in cerebrospinal fluid (CSF) from baseline to 48 weeks. Lower ab40 is associated with a greater probability of fibrillar amyloid burden in the brain. (NCT03061474)
Timeframe: Baseline to 48 weeks

Change in ab42

Intervention	pg/ml (Mean)
Nicotinamide	2307
Placebo	1961.1

Change in key peptide in cerebrospinal fluid (CSF) from baseline to 48 weeks. Lower ab42 is associated with a greater probability of fibrillar amyloid burden in the brain. (NCT03061474)
Timeframe: Baseline to 48 weeks

Change in P-tau 181

Intervention	pg/ml (Mean)
Nicotinamide	127.74
Placebo	113.79

Change in key peptide in cerebrospinal fluid (CSF) from baseline to 48 weeks. Higher total value is associated with greater severity of Alzheimer's disease pathology. (NCT03061474)
Timeframe: Baseline to 48 weeks

Change in P-tau 231

Intervention	pg/ml (Mean)
Nicotinamide	-0.41
Placebo	-10.43

Change in key peptide in cerebrospinal fluid (CSF) from baseline to 48 weeks. Higher phosphorylated tau (p-tau) is associated with a severity of Alzheimer's disease pathology. (NCT03061474)
Timeframe: Baseline to 48 weeks

Change in QTC

Intervention	pg/ml (Mean)
Nicotinamide	4.71
Placebo	2.28

Average within-subject change in electrocardiogram QT interval. (NCT03061474)
Timeframe: Baseline to 48 weeks

Change in Ratio of Total Tau/ab40

Intervention	ms (Mean)
Nicotinamide	6.41
Placebo	2.1

Change in ratio of key peptides in cerebrospinal fluid (CSF) from baseline to 48 weeks. A lower ab40/tau ratio is associated with a higher risk of dementia. (NCT03061474)
Timeframe: Baseline to 48 weeks

Change in Ratio of Total Tau/ab42

Intervention	ratio (Mean)
Nicotinamide	-0.02
Placebo	-0.02

Change in ratio of key peptides in cerebrospinal fluid (CSF) from baseline to 48 weeks. A lower ab42/tau ratio is associated with a higher risk of dementia. (NCT03061474)
Timeframe: Baseline to 48 weeks

Change in Total Tau

Intervention	ratio (Mean)
Nicotinamide	-0.46
Placebo	-0.5

Change in CSF total tau in individuals with mild Alzheimer's disease (AD) dementia or Mild Cognitive Impairment due to AD. (NCT03061474)
Timeframe: Baseline to 48 weeks

Count of Treatment Emergent Adverse Events

Intervention	pg/ml (Mean)
Nicotinamide	-8.42
Placebo	-60.47

Count of treatment emergent adverse events (TEAEs) over the duration of the study period (baseline to 48 weeks). (NCT03061474)
Timeframe: Baseline to 48 weeks

ECG Abnormalities

Intervention	events (Number)
Nicotinamide	79
Placebo	71

Count of participants experiencing at least one electrocardiogram (ECG) abnormality. (NCT03061474)
Timeframe: Baseline to 48 weeks

QTC Abnormalities

Intervention	Participants (Count of Participants)
Nicotinamide	24
Placebo	20

Count of participants experiencing at least one electrocardiogram (ECG) QT interval abnormality. Abnormal defined as above 460 for men and above 470 for women. (NCT03061474)
Timeframe: Baseline to 48 weeks

Columbia-Suicide Severity Rating Scale

Intervention	Participants (Count of Participants)
Nicotinamide	2
Placebo	1

"The Columbia-Suicide Severity Rating Scale (C-SSRS) captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the corresponding assessment period. The scale includes suggested questions to elicit the type of information needed to determine if a suicide-related thought or behavior occurred. The number and proportion of subjects with treatment emergent Suicidal ideation or behavior during the study period of (baseline to week 48) will be reported overall and by study arm. Treatment emergent suicidal ideation or behavior is defined as a yes answer at any time during treatment to any one of the questions in the ten suicidal ideation and behavior categories (Categories 1- 10) on the C-SSRS. Self-injurious behavior without suicidal intent, while assessed on the C-SSRS, does not form part of this outcome." (NCT03061474)
Timeframe: Baseline to 48 weeks

Count of Adverse Events by Severity

Intervention	events (Number)
	Baseline Number of abnormal C-SSRS events	Post-baseline number of abnormal C-SSRS events
Nicotinamide	0	1
Placebo	3	3

Count of treatment emergent adverse events (TEAEs) over the duration of the study period (baseline to 48 weeks). (NCT03061474)
Timeframe: Baseline to 48 weeks

Vital Signs - BMI

Intervention	events (Number)
	Mild	Moderate	Severe	Total
Nicotinamide	49	27	3	79
Placebo	38	31	2	71

Body Mass Index (BMI) was recorded at every study visit (screening, baseline, week 12, week 24, and week 48) (NCT03061474)
Timeframe: Screening through end of study (week 48)

Vital Signs - Diastolic Blood Pressure

Intervention	kg/m^2 (Mean)
	Screening Visit	Baseline Visit	Week 12 Visit	Week 24 Visit	Week 48 Visit
Nicotinamide	26.35	26.33	26.42	26.52	26.24
Placebo	24.09	24.85	24.72	25.08	24.68

Diastolic blood pressure was recorded at every study visit (screening, baseline, week 12, week 24, and week 48) (NCT03061474)
Timeframe: Screening through end of study (week 48)

Vital Signs - Pulse

Intervention	mm Hg (Mean)
	Screening Visit	Baseline Visit	Week 12 Visit	Week 24 Visit	Week 48 Visit
Nicotinamide	75.42	74.21	72.45	75.2	71.9
Placebo	71.32	70.45	71.4	71.4	69.74

Pulse rate was recorded at every study visit (screening, baseline, week 12, week 24, and week 48) (NCT03061474)
Timeframe: Screening through end of study (week 48)

Vital Signs - Systolic Blood Pressure

Intervention	bpm (Mean)
	Screening Visit	Baseline Visit	Week 12 Visit	Week 24 Visit	Week 48 Visit
Nicotinamide	56.42	59.33	58.86	58.6	59.57
Placebo	62.5	64.91	63.45	62.26	64.84

Systolic blood pressure was recorded at every study visit (screening, baseline, week 12, week 24, and week 48) (NCT03061474)
Timeframe: Screening through end of study (week 48)

Vital Signs - Weight

Intervention	mm Hg (Mean)
	Screening Visit	Baseline Visit	Week 12 Visit	Week 24 Visit	Week 48 Visit
Nicotinamide	134.67	137.42	133.36	130.4	129.43
Placebo	126.09	125.41	128.05	130.16	129.37

Weight in kg was recorded at every study visit (screening, baseline, week 12, week 24, and week 48) (NCT03061474)
Timeframe: Screening through end of study (week 48)

Complete Response

Intervention	kg (Mean)
	Screening Visit	Baseline Visit	Week 12 Visit	Week 24 Visit	Week 48 Visit
Nicotinamide	76.39	76.29	77.27	76.88	76.43
Placebo	68.11	70.05	69.36	72.22	70.27

Analysis of the Primary Endpoint: The complete responses will be estimated by the number of patients with CR divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 4 cycles

Overall Response Rate

Intervention	Percentage of Participants (Number)
FCR With Lenalidomide	45

Analysis of the other Secondary Endpoints: The overall response rate will be estimated by the number of patients with complete and partial responses divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 6 cycles

Article	Year
Nicotinamide Riboside for the Prevention and Treatment of Doxorubicin Cardiomyopathy. Opportunities and Prospects. Nutrients, 2021, Sep-28, Volume: 13, Issue:10 Topics: Animals; Antibiotics, Antineoplastic; Biomarkers; Cardiomyopathies; Cardiotonic Agents; Cardiotoxici	2021
Balancing NAD Cellular and molecular life sciences : CMLS, 2022, Aug-02, Volume: 79, Issue:8 Topics: Animals; Disease Models, Animal; Mice; NAD; Niacinamide; Pyridinium Compounds	2022
Can nicotinamide riboside protect against cognitive impairment? Current opinion in clinical nutrition and metabolic care, 2020, Volume: 23, Issue:6 Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Brai	2020
Protective Effects of Nicotinamide Adenine Dinucleotide and Related Precursors in Alzheimer's Disease: A Systematic Review of Preclinical Studies. Journal of molecular neuroscience : MN, 2021, Volume: 71, Issue:7 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents; Apoptosis; Behavior, An	2021
Vitamin B The Tohoku journal of experimental medicine, 2018, Volume: 244, Issue:3 Topics: Animals; Disease Models, Animal; Female; Fetal Development; Humans; Niacinamide; Pre-Eclampsia; Preg	2018
Novel therapeutic approaches to xeroderma pigmentosum. The British journal of dermatology, 2019, Volume: 181, Issue:2 Topics: Acetohexamide; Administration, Cutaneous; Animals; Caloric Restriction; Dermatology; Disease Models,	2019
Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotection. Current opinion in clinical nutrition and metabolic care, 2013, Volume: 16, Issue:6 Topics: Alzheimer Disease; Animals; Brain; Disease Models, Animal; Energy Metabolism; Humans; Insulin Resist	2013
Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotection. Current opinion in clinical nutrition and metabolic care, 2013, Volume: 16, Issue:6 Topics: Alzheimer Disease; Animals; Brain; Disease Models, Animal; Energy Metabolism; Humans; Insulin Resist	2013
Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotection. Current opinion in clinical nutrition and metabolic care, 2013, Volume: 16, Issue:6 Topics: Alzheimer Disease; Animals; Brain; Disease Models, Animal; Energy Metabolism; Humans; Insulin Resist	2013
Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotection. Current opinion in clinical nutrition and metabolic care, 2013, Volume: 16, Issue:6 Topics: Alzheimer Disease; Animals; Brain; Disease Models, Animal; Energy Metabolism; Humans; Insulin Resist	2013
Nicotinamide and neurocognitive function. Nutritional neuroscience, 2015, Volume: 18, Issue:5 Topics: Animals; Cognition; Dietary Supplements; Disease Models, Animal; Humans; Neurocognitive Disorders; N	2015
Design and Reporting of Targeted Anticancer Preclinical Studies: A Meta-Analysis of Animal Studies Investigating Sorafenib Antitumor Efficacy. Cancer research, 2016, 08-15, Volume: 76, Issue:16 Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Neoplasms; Niacinamide; Phenylurea Compounds	2016
[Rosacea 2009 : new advances in pathophysiology, clinical staging and therapeutic strategies]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2009, Volume: 60, Issue:12 Topics: Adult; Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Cathelicidins; Dermatologic	2009
Raf inhibitors as therapeutic agents against neurodegenerative diseases. CNS & neurological disorders drug targets, 2010, Volume: 9, Issue:1 Topics: Animals; Benzenesulfonates; Brain; Disease Models, Animal; Drug Design; Encephalitis; Humans; Inflam	2010
Developing better treatments in hepatocellular carcinoma. Expert review of gastroenterology & hepatology, 2010, Volume: 4, Issue:5 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Top	2010
Targeting angiogenesis in esophagogastric adenocarcinoma. The oncologist, 2011, Volume: 16, Issue:6 Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu	2011
Nicotinamide: a jack of all trades (but master of none?). Intensive care medicine, 2003, Volume: 29, Issue:6 Topics: Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Hemodynamics; Humans; Niacinamide; Ox	2003
Pooling of animal experimental data reveals influence of study design and publication bias. Stroke, 2004, Volume: 35, Issue:5 Topics: Animals; Brain Ischemia; Disease Models, Animal; Humans; Meta-Analysis as Topic; Neuroprotective Age	2004
Micronutrients and the risk of type 1 diabetes: vitamin D, vitamin E, and nicotinamide. Nutrition reviews, 2004, Volume: 62, Issue:9 Topics: Animals; Diabetes Mellitus, Type 1; Disease Models, Animal; Humans; Micronutrients; Niacinamide; Ris	2004
[Characteristics of N-methyl-N-nitrosourea-induced retinal degeneration in animals and application for the therapy of human retinitis pigmentosa]. Nippon Ganka Gakkai zasshi, 2005, Volume: 109, Issue:6 Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspases; Cricetinae; Disease Models, Animal; Docosa	2005
Raf kinases: oncogenesis and drug discovery. International journal of cancer, 2006, Nov-15, Volume: 119, Issue:10 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Disease Models, Animal;	2006
Neurochemistry and toxin models in Huntington's disease. Current opinion in neurology, 1994, Volume: 7, Issue:6 Topics: Animals; Coenzymes; Disease Models, Animal; Energy Metabolism; Humans; Huntington Disease; Mitochond	1994
[Elucidation of paraquat poisoning mechanism and development of the neuronal death model]. Nihon eiseigaku zasshi. Japanese journal of hygiene, 2002, Volume: 57, Issue:1 Topics: Animals; Chaperonin 60; Disease Models, Animal; Electron Transport Complex I; Herbicides; Humans; Li	2002
Potassium channel activator drugs: mechanism of action, pharmacological properties, and therapeutic potential. Medicinal research reviews, 1992, Volume: 12, Issue:2 Topics: Animals; Antihypertensive Agents; Benzopyrans; Cardiovascular System; Central Nervous System; Clinic	1992
A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1991, Volume: 22, Issue:2 Topics: Adenocarcinoma; Animals; Carbon; Disease Models, Animal; Dose-Response Relationship, Radiation; In V	1991

Article	Year
Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma. Blood, 2013, Sep-19, Volume: 122, Issue:12 Topics: Acetylation; Adult; Aged; Animals; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Eva	2013
Oxalic acid and diacylglycerol 36:3 are cross-species markers of sleep debt. Proceedings of the National Academy of Sciences of the United States of America, 2015, Feb-24, Volume: 112, Issue:8 Topics: Animals; Biomarkers; Circadian Rhythm; Diglycerides; Disease Models, Animal; Energy Metabolism; Fema	2015
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet (London, England), 2004, Mar-20, Volume: 363, Issue:9413 Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Disease Models, Animal; Double-Blind Method; Europe;	2004
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet (London, England), 2004, Mar-20, Volume: 363, Issue:9413 Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Disease Models, Animal; Double-Blind Method; Europe;	2004
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet (London, England), 2004, Mar-20, Volume: 363, Issue:9413 Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Disease Models, Animal; Double-Blind Method; Europe;	2004
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet (London, England), 2004, Mar-20, Volume: 363, Issue:9413 Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Disease Models, Animal; Double-Blind Method; Europe;	2004
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet (London, England), 2004, Mar-20, Volume: 363, Issue:9413 Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Disease Models, Animal; Double-Blind Method; Europe;	2004
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet (London, England), 2004, Mar-20, Volume: 363, Issue:9413 Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Disease Models, Animal; Double-Blind Method; Europe;	2004
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet (London, England), 2004, Mar-20, Volume: 363, Issue:9413 Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Disease Models, Animal; Double-Blind Method; Europe;	2004
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet (London, England), 2004, Mar-20, Volume: 363, Issue:9413 Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Disease Models, Animal; Double-Blind Method; Europe;	2004
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet (London, England), 2004, Mar-20, Volume: 363, Issue:9413 Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Disease Models, Animal; Double-Blind Method; Europe;	2004

niacinamide and Disease Models, Animal

Research Excerpts

Research

Studies (417)

Authors

Clinical Trials (24)

Trial Overview

Trial Outcomes

Safety and Tolerability of RJX as Assessed by Electrocardiograms (ECGs).

Safety and Tolerability of RJX as Assessed by Neurological Examinations.

Treatment-related Adverse Events (TEAE) Reporting of RJX

Difference in Score Between Baseline and End of Treatment for the FACT&GOG-NTX Subscale .

Difference in Total Neuropathy Score Between Screening and End of Treatment

Number of Dose Reduction Events

Number of Participants With No Worsening in the Grade of Peripheral Sensory Neuropathy as Scored by CTCAE

Percentage of Patients in Which Dose of Paclitaxel or Nab-Paclitaxel is Reduced Due to CIPN

Plasma Concentration of Paclitaxel After NIAGEN Treatment Began

Total Dose of Paclitaxel Administered

The Greatest Number of Cycles Received in Each Treatment Group

The Maximum Tolerated Dose (MTD) of Niacinamide in the Combination of Vorinostat and Niacinamide

The Median Progression Free Survival Time Will be Determined.

The Median Survival Time Will be Determined.

One- and Two-year Overall Survival Rate Will be Determined.

One- and Two-year Progression Survival Rate Will be Determined. Will be Determined.

The Quality of Life Will be Analyzed.

Treatment-related Adverse Effects Will be Determined.

Activities of Daily Living - Mild Cognitive Impairment

ADASCog-13

CDR Sum of Boxes

Change in ab40

Change in ab42

Change in P-tau 181

Change in P-tau 231

Change in QTC

Change in Ratio of Total Tau/ab40

Change in Ratio of Total Tau/ab42

Change in Total Tau

Count of Treatment Emergent Adverse Events

ECG Abnormalities

QTC Abnormalities

Columbia-Suicide Severity Rating Scale

Count of Adverse Events by Severity

Vital Signs - BMI

Vital Signs - Diastolic Blood Pressure

Vital Signs - Pulse

Vital Signs - Systolic Blood Pressure

Vital Signs - Weight

Complete Response

Overall Response Rate

Reviews

Trials

Other Studies